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Abstract 
 
The unique chemical properties of fluorine atom (high 
electronegativity, high ionization potential, low polarizability and low 
van der Waals interactions) modify the chemical properties of organic 
compounds as well as their reactivity when hydrogen atoms are 
replaced by fluorines. Actually, fluorocarbons show low polarity, which 
is responsible for the high hydrophobicity of these molecules. 
Additionally, the low polarizability of fluorines leads to weaker van der 
Waals interactions, which makes fluorocarbons lipophobic. Therefore, 
fluorinated compounds show an amphiphilic character that leads to the 
formation of the fluorous phase, which is separated to both aqueous 
and organic layers. 
The aim of my project was applying the strong and noncovalent 
fluorous interactions to drug discovery and drug delivery. 
 
iii 
 
The first part of my thesis is focused on the development of a new 
strategy for target identification able to overcome the several limitations 
associated to classic chemical proteomics techniques. Indeed, traditional 
chemical proteomics methodology uses agarose beads covalently 
bound to streptavidin as stationary phase for affinity purification. This 
resin is able to retain biotin-tagged proteins as well as sticky 
components abundant in the lysate. These contaminants might be 
aspecifically eluted with the biological targets, complicating the mass 
analysis and therefore the target identification. In order to increase the 
selectivity of the proteomics approach, we designed an innovative 
fluorous proteomics methodology using the strong fluorous-fluorous 
interactions as recognition system for affinity purification. Indeed, 
perfluorinated stationary phase can anchor only fluorinated species, 
avoiding aspecific binding. To test the fluorous proteomics approach, 
papain was considered as biological target. Fluorinated inhibitors of 
papain with different fluorinated-chain length were synthesized. The 
number of fluorine atom of the inhibitor is crucial for the interaction 
with the fluorinated stationary phase in the purification step. Actually, 
only papain inhibitors with a long fluorous alkyl chain are able to bind 
the fluorinated resin and therefore immobilize papain. In contrast, 
inhibitors with a short fluorous alkyl chain cannot bind the fluorinated 
stationary phase by means of fluorous-fluorous interactions. 
Consequently, papain cannot be anchored to the resin. 
 
The second part of my thesis is focused on the application of fluorous 
interactions for drug delivery. This project was carried out in the School 
of Pharmacy, University of Wisconsin-Madison (Madison, WI, U.S.A.) 
under the supervision of Professor Sandro Mecozzi. The aim was 
designing and synthesizing semifluorinated dibranched polymers. The 
iv 
 
synthesis of fluorinated molecules is a challenge, due to their poor 
reactivity and low solubility in commonly-used organic solvents.  To 
increase the final yield, each step of the synthesis of the semifluorinated 
dibranched polymers was optimized. The dibranched fluorinated 
polymers will be used to prepare oil-in-water nanoemulsions for 
controlled drug release of paclitaxel. We reasoned that semifluorinated 
polymers with different chemical structures might lead to 
nanoemulsions with different stability and drug release profile. Small 
diameter of the nanoemulsion droplets and long half-lives are desired 
to maximize the tumoritropic accumulation of these nanosystems by 
EPR effect before drug release. This allows the release of the drug 
within the tumor instead of in the bloodstream, avoiding side effects 
due to the interaction of the drug with off targets and consequently 
reducing the systemic toxicity.   
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Chapter 1 
 
Introduction 
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1.1 Historical Development 
 
Elemental fluorine was isolated by Henry Moissan in 1886. However, 
the industrial production of fluorine began during World War II, when 
isotopic enrichment of natural uranium into its radioactive isotope was 
required in order to build nuclear weapons. For this purpose, high-
temperature electrolysis was applied to prepare large quantities of 
elemental fluorine and fluorhydric acid needed to get uranium 
hexafluoride (UF6), which is used for uranium enrichment. This led to 
the birth of fluorine industry.1 
Industrial application of fluorinated organic molecules started with the 
market of Freon-12 (CCl2F2) by General Motors to replace more toxic 
compounds used in kitchen refrigerators. Polytetrafluoroethylene 
(TeflonTM) was serendipitously discovered by Dr. Roy Plunkett in 1938 
while working on refrigerants. An accidental polymerization afforded a 
waxy substance showing unique chemical and physical properties.2 In 
fact, TeflonTM is characterized by high thermal stability, exceptional 
mechanical properties at extreme temperatures, excellent chemical 
resistance and dielectric properties, oil and water repellence and low 
flammability.3 Thanks to these properties, TeflonTM has found several 
applications, such as electrical cable insulation, stain repellant, non-
stick coating for cookware and lubrificant.4 It is also applied in the 
medical field as graft material in surgery, heart patches and coating on 
catheters, since it prevents the adhesion of bacteria on the catheter 
surface avoiding hospital-acquired infections.5  
For many years, fluorine chemistry remained confined to the field of 
polymers and materials rather than medicinal chemistry. Organic 
fluorinated compounds are not common in nature. It is remarkable that 
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fluorine is present in less than 15 natural products and the only one 
known at that time was fluoroacetic acid, a potent poison.1,6 For these 
reasons, the investigation of fluorinated-drug field started later, in the 
early 1950s. It is noteworthy that the introduction of a single fluorine 
atom in a drug can modify deeply its biological properties. In fact, in 
1957 Dr. Charles Heidelberger demonstrated that 5-fluorouracil (5-FU) 
– synthesized by introducing a fluorine atom in the 5 position of uracil – 
was able to inhibit the thymidylate synthase. This blocked the synthesis 
of thymidine and, consequently, the synthesis of DNA.7,8  
Nowadays, 20% of pharmaceuticals on the market contains fluorine. 
Atorvastatin – HMGCoA reductase inhibitor used to treat 
hypercholesterolaemia – was the most sold drug worldwide in 2012. It 
went on market in 1997 and over 15 years, atorvastatin has been made 
over $125 billion in sales.9 Many selective serotonin reuptake inhibitors 
contain fluorine atoms. In fact, it was demonstrated that the presence of 
a trifluoromethyl group in para position in the aromatic ring of 
fluoxetine gives selectivity toward the serotonin transport.10 Other 
examples of best-seller fluorinated drugs are ciprofloxacin (a broad-
spectrum antibiotic belonging to the quinolone class), lansoprazole (a 
proton-pump inhibitor) and fluticasone propionate (a glucocorticoid 
used to treat asthma and allergic rhinitis).8 The interest for fluorine in 
medicinal chemistry has been increased in the recent years. Actually, 
new fluorinated drugs have been approved by FDA or are under 
clinical study. Among them, afatinib (approved in 2015) and 
dacomitinib (phase III study) are active against non-small-cell lung 
carcinoma while evacetrapib and darapladib (both in phase III study) 
are under development as drugs for treatment of atherosclerosis.11,12,13,14  
3 
 
1.2 Properties of Fluorine 
 
The structure and the atomic properties of fluorine atom affect deeply 
both chemical and physical characteristics of fluorinated molecules. 
Fluorine is the most electronegative element in the periodic table and 
shows very high ionization potential and very low polarizability.1 
When bound to carbon, it forms the strongest bond in organic 
chemistry.15 The extreme stability of C-F bond is increased when the 
number of fluorine atoms bound to the same carbon atom increases. 
This improved stabilization is found also in the length of C-F bonds in 
the series CH3F (140 pm) > CH2F2 (137 pm) > CHF3 (135 pm) > CF4 (133 
pm). The main reason for this stabilization is the excellent overlap 
between the fluorine 2s and 2p orbitals with the corresponding carbon 
orbitals; this allows the occurrence of dipolar resonance structures for 
multiply fluorine-substituted carbon, as shown in Figure 1.1.2 
 
 
Figure 1.1 Resonance stabilization of C-F bond in CF4. The electrostatic 
potentials are mapped on the electron isodensity surface (calculation at the 
MP2/6-31+G* level of theory; red denotes negative and blue positive partial 
charges).2 
 
Because of the high electronegativity of fluorine, C-F bond is polarized 
from the sp3 carbon (δ+) to the fluorine (δ-) that is in the opposite 
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direction of C-H bond. The high electronegativity and the low 
polarizability of the fluorine atom are responsible for the ionic character 
of C-F bond as well as the stronger energy of this bond if compared 
with the bond between carbon and the other halogens. Moreover, the 
low polarizability implies lower van der Waals interactions, often 
increasing local lipophilicity of a molecule despite the higher 
electronegativity.15 
Fluorine shows a greater van der Waals radius (1.47 Å) than hydrogen 
(1.20 Å), being actually closer to that of oxygen (1.52 Å).16 The larger 
volume of fluorine than hydrogen volume is responsible for the 
molecular steric congestion observed when hydrogens are replaced 
with fluorines. In particular, replacing a single hydrogen with fluorine 
has limited steric effect and this does not affect the conformation of the 
whole molecule. However, the substitution of a methylene (CH2) with a 
difluoromethylene group (CF2) can lead to a dramatic modification in 
conformation.17 
Table 1.1 summarizes some properties of hydrogen, fluorine and 
oxygen. 
 
Atom 
Pauling’s 
Electronegativity 
Bond 
Length 
(CH2-X, 
Å) 
Van 
der 
Waals 
Radius 
(Å) 
Bond 
Energy 
(CH2-X, 
kcal/mol) 
Ionization 
Potential 
(kcal/mol) 
Atom 
Polarizability 
(Å3) 
H 2.20 1.09 1.20 99 313.6 0.667 
F 3.98 1.39 1.47 116 401.8 0.557 
O 3.44 1.43 1.52 85 314.0 0.82 
Table 1.1 Properties of hydrogen, fluorine and oxygen. 
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1.3 Physical Properties of Fluorinated Molecules 
 
The physical properties of fluorinated molecules depends mainly on the 
high electronegativity of fluorine, its small size and its very low 
polarizability. As mentioned before, C-F bond is strongly polarized. 
However, perfluorocarbons (PFCs) are nonpolar. In fact, local dipole 
moments within the same molecule cancel out, leading to a nonpolar 
molecule.2 
Due to the low polarizability, fluorinated molecules – even the lightly 
fluorinated compounds – show weak intra- and intermolecular 
interactions. Consequently, they are characterized by very high vapor 
pressure if compared to that of their hydrogenated analogues. This 
means that fluorinated molecules are volatile.1 Perfluorinated 
compounds have lower boiling points than hydrocarbons with similar 
molecular weights. If perfluorinated compounds and homologous 
hydrocarbons are compared, they show similar boiling points. 
However, the molecular masses of PFCs are about four times higher 
than hydrocarbons ones, as shown in Figure 1.2.2 
 
 
Figure 1.2 The boiling points of homologous alkanes (    ) compared with those 
of the corresponding perfluoroalkanes (       ).2 
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It is noteworthy that branching does not affect the boiling point 
strongly. The boiling point of PFCs is only 25-30 °C higher than that of 
noble gases with similar molecular weights. This is due to the low 
polarization that affords a “perfect” fluid behavior to these molecules. 
The boiling points of fluoromethanes do not increase according to the 
number of fluorines present in the molecule, conversely to the boiling 
points of chloro- and bromomethanes. As shown in Table 1.2, the 
boiling point increases from CH4 to CH2F2 and then decreases until 
CF4.1 
 
Compound 
Boiling 
point 
(°C) 
Compound 
Boiling 
point 
(°C) 
Compound 
Boiling 
point 
(°C) 
CH4 -161 CH4 -161 CH4 -161 
CH3F -78.6 CH3Cl -24.2 CH3Br 3.6 
CH2F2 -51.6 CH2Cl2 40.1 CH2Br2 98.2 
CHF3 -82.2 CHCl3 61.3 CHBr3 149.5 
CF4 -128 CCl4 98.2 CBr4 189.5 
Table 1.2 Boiling points of halomethanes.1 
 
Hemifluorinated molecules have local carbon-fluorine dipole moments 
that generate strong electrostatic interactions. Moreover, a correlation is 
observed between boiling points and dipolar moments. Actually, 
comparing the boiling point of methane and fluoromethanes, it results 
that nonpolar CH4 and CF4 show the lowest boiling points while CH2F2 
– which has the strongest molecular dipole moments – has the highest 
boiling point. Figure 1.3 illustrates the relationship between dipole 
moment and boiling point for methane and fluoromethane series.1,2 
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Figure 1.3 Boiling points (gray bars) and dipole moments (   , values in italics) 
of methane and the different fluoromethanes CH4-nFn.2 
 
Weak intermolecular interactions are also responsible for the very low 
surface tension (γ) of perfluorinated compounds. In fact, they always 
show a lower surface tension than the one of the corresponding 
hydrocarbons. Consequently, PFCs can wet any surface. Moreover, the 
introduction of a polar hydrophilic group in a perfluorinated alkyl 
chain affords a very active fluorosurfactant that can reduce the surface 
tension of water from 72 dyn/cm to 15-20 dyn/cm compared with 25-
35 dyn/cm for the corresponding hydrocarbon surfactant.2 Similarly, 
the critical micelle concentration (CMC) of fluorinated surfactants is 
lower than their hydrogenated counterparts CMC.18 It has been 
estimated that the contribution of a CF2 in a linear fluorocarbon chain 
towards the energy of micellization is equivalent to 1.5 CH2 in a linear 
hydrocarbon chain. Fluorinated amphiphiles can self-assemble into 
Langmuir monolayers, spherical or cylindrical micelles, and bilayer 
pyramidal columns in organic, aqueous, or fluorous solvents.15,19,20 
However, these systems show different properties if compared with the 
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ones obtained from hydrogenated analogues. Because of the greater van 
der Waals radius of fluorine than hydrogen radius, perfluoroalkyl 
chains are bulkier than the hydrocarbon counterpart. Consequently, 
disk-like and rod-like cylindrical micelles are preferred than spherical 
micelles.21 
 
1.4 Reactivity and Chemical Properties of Fluorinated Molecules 
 
C-F bond is thermodynamically stabilized by the optimum overlap 
between the 2s and 2p orbitals of fluorine and the corresponding 
orbitals of carbon. In PFCs, there is also a kinetic stability coming from 
the steric shielding of the central carbon atom by the fluorine 
substituents.2,15 Actually, the three electron lone pairs of fluorine atom 
and the negative partial charge represent a steric and electrostatic shield 
against nucleophilic attack of the central carbon atom. Moreover, CF3 
group is much more sterically demanding than CH3 substituent and is 
bulkier than isopropyl group. This is more easily understandable 
comparing the van der Waals volumes of CH3 (16.8 Å3) and CF3 (42.6 
Å3), as shown in Figure 1.4. The steric hindrance and the electrostatic 
shield arising from the presence of many adjacent fluorines bound to a 
carbon backbone is the major responsible factor for the relative 
inertness of PFCs.2,22 
 
 
 
            
 
 
Figure 1.4 Van der Waals volumes of CH3 and CF3 groups.22  
16.8 Å
3
 42.6 Å
3
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Fluoroalkyl substituents have always a strong electron-withdrawing 
effect. Consequently, they increase the acidity of neighboring hydrogen 
atoms (Table 1.3). As expected, the inductive effect falls off with 
distance, while the presence of a double bond relays the effect. The 
strong inductive effect of fluoroalkyl substituents increases the acidity 
of alcohols (Table 1.3). It is noteworthy that perfluoro-t-butanol has a 
pKa value close to acetic acid pKa. Fluorine atoms bound to a phenyl 
ring are not only inductively electron-withdrawing since their electron 
lone pairs can be donated to the aromatic ring through resonance. 
 
Carboxylic acid pKa Alcohol pKa 
CH3COOH 4.76 CH3CH2OH 15.9 
CH2FCOOH 2.59 CF3CH2OH 12.4 
CHF2COOH 1.34 CCl3CH2OH 12.2 
CF3COOH 0.52 (CF3)2CHOH 9.3 
CF3CH2CH2COOH 4.15 (CH3)3COH 19.2 
CF3CH=CHCOOH 3.48 (CF3)3COH 5.1 
C6H5COOH 4.21 C6H5OH 10.0 
C6F5COOH 1.75 C6F5OH 5.5 
Table 1.3 pKa values of some carboxylic acids and alcohols.2,22 
 
The inductive effect of fluorination lowers the strength of organic bases 
(Table 1.4). Tertiary perfluoroalkylamines do not show basic properties. 
Actually, perfluoroethylamine can be used as solvent in reaction 
involving Lewis acid like TiCl4 or BF3, without observing a reaction 
between the fluorinated base and the Lewis acid.22 
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Amine pKb 
CH3CH3NH2 3.3 
CF3CH2NH2 8.1 
C6H5NH2 9.4 
C6F5NH2 14.36 
Table 1.4 pKb values of some amines.2,22 
 
Despite the electron lone pairs and the high electronegativity, fluorine 
is a poor acceptor of hydrogen bond because of the low polarization of 
its s and p electrons.2 
The introduction of fluorines in aromatic systems changes the 
electrostatic distribution of the molecular surface deeply. Noteworthy, 
the fluorination of aromatic rings in molecules of pharmaceutical 
interest may create new binding sites localized in proximity of the 
fluorine atoms.23 For that reason, mono- or difluorination of phenyl 
groups in drugs can improve the protein binding. For example, it was 
demonstrated that fluorinated inhibitors and HMGCoA reductase form 
complexes involving an ion-dipole interaction between an aromatic 
fluorine and the guanidinium side chain of Arg590 (Figure 1.5). The 
distance F···N was found to be 2.9 Å.23,24 
 
Figure 1.5 Ion-dipole bond between atorvastatin and Arg590 in the binding 
pocket of HMGCoA reductase. 
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Moreover, a systematic scan of substituents belonging to the series of 7-
(substituted aryl)-3,5-dihydroxy-6-heptenoic (and heptanoic) acids and 
their lactones demonstrated that the inhibitors showing the highest 
activity borne a 4-fluorophenyl moiety.23 This suggests that aromatic 
fluorine can play an important role in the activity of molecules with 
medicinal interest. 
 
1.5 Perfluorocarbons 
 
Horváth and Rábai introduced the term “fluorous” in 1994 in analogy 
to “aqueous”.25 Fluorous was defined as “of, relating to, or having the 
characteristics of highly fluorinated saturated organic materials, 
molecules, or molecular fragments”;26 that means PFCs are fluorous 
molecules. PFCs are more chemically and thermally stable than 
hydrocarbons since the strong C-F bond gets stronger because of the 
high degree of fluorination, rising from 116 kcal/mol up to 127 
kcal/mol in PFCs.27 An additional element of stability is represented by 
the steric hindrance arising from the coating of fluorine substituents, 
since it protects the carbon backbone against nucleophilic attack.28 The 
low polarization and the larger size of fluorine compared to hydrogen 
(1.47 Å vs 1.20 Å) affect the molecular conformation of PFCs.2 Actually, 
mean volumes of CF2 and CF3 groups are estimated to be 38 Å3 and 92 
Å3, while mean volumes of CH2 and CH3 groups are 27 Å3 and 54 Å3 
respectively.29 Moreover, the CF3 group is larger than an isopropyl 
substituent.29 For these reasons, fluorinated chains are bulkier than 
alkyl chains, with cross sections around 27-30 Å2 and 18-21 Å2 
respectively.29 The steric repulsion between fluorine atoms bound to the 
carbon backbone in the relative 1,3-positions as well as the larger van 
der Waals radius of fluorine cause a stretching and a twisting of the 
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carbon backbone by 12° on average.29,30 This results in a 15/7 helix, with 
left and right helices being in equal proportions.29 This is the reason 
why perfluoroalkyl chains adopt an all-trans helical structure rather 
than the planar “zig-zag” conformation of linear hydrocarbons (Figure 
1.6).2 The repulsive stretching of 1,3-difluoromethylene groups is also 
responsible for the rigidity of perfluoroalkyl chains. In fact, PFCs are 
rigid, rod-like molecules since they lack the conformational flexibility of 
hydrocarbons. It has been demonstrated that trans/gauche interchange 
enthalpies are at least 25% higher for linear PFCs than for the non-
fluorinated analogue, and this reduces the conformational freedom of 
perfluoroalkyl chains.29 Consequently, PFCs show higher level of 
packing if compared to hydrocarbons, which is responsible for the 
assembly properties of PFCs. 
 
 
Figure 1.6 The linear “zig-zag” conformation of octadecane compared with the 
helical perfluorooctadecane.2 
 
Due to the very low polarizability of fluorine, van der Waals 
interactions between perfluoroalkyl chains are very weak.15 As a result, 
the cohesive energy in liquid PFCs are low. Weak van der Waals 
interactions are responsible for many properties of PFCs, such as very 
low surface tension, high fluidity, low dielectric constant, high vapor 
pressure, high compressibility, and high gas solubilities.31,32 
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Intermolecular interactions can be quantified by the Hildebrand 
parameter (δ), calculated as the root square of the cohesive energy 
density of a liquid. The cohesive energy density is correlated to the 
polarity of the molecules. For low molecular weight compounds, the 
cohesive energy density is the energy of vaporization in calories per 
cubic centimeter and is an evaluation of the degree of van der Waals 
forces between molecules in the liquid. The lower the Hildebrand 
parameter is, the weaker the intermolecular interactions are.33 It is 
remarkable that molecules with similar δ are miscible with or soluble in 
one another. Table 1.5 lists δ for some perfluorinated and non-
fluorinated solvents. 
 
Solvent δ (MPa1/2) 
O2 11.4 
Perfluorohexane 12.1 
Perfluoroheptane 12.3 
Perfluoro(methylcyclohexane) 12.5 
Hexane 14.9 
α,α,α-Trifluorotoluene 16.8 
Toluene 18.2 
Cyclohexane 18.8 
Benzene 18.8 
Acetonitrile 24.3 
Methanol 29.7 
Water 48.0 
Table 1.5 Hildebrand parameters (δ) for perfluorinated and non-fluorinated 
solvents.33,29, 34  
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Because of the disparity in cohesive energy densities between liquid 
PFCs and liquid non-fluorinated hydrocarbons, these entities are not 
miscible.29 It is remarkable that PFCs show amphiphilic properties. The 
local dipole moments of each C-F bond within the same molecule cancel 
out, leading to a hydrophobic character. Additionally, low van der 
Waals interactions give a lipophobic behavior. This amphiphilic 
character provides the driving force to PFCs to segregate away from 
both polar and non-polar solvents.35 Consequently, when PFCs are 
mixed with water and organic solvents, they usually form a unique 
phase called the fluorous phase, which is separated to both the aqueous 
and the organic layers (Figure 1.7). This allows PFCs to make stronger 
intermolecular interactions with each other. Molecules showing this 
kind of behavior are called fluorophilic, in analogy to hydrophilic and 
lipophilic. 
 
 
Figure 1.7 Schematic representation of the fluorous phase formation. 
 
The term “fluorophilicity” is referred to the affinity of a given 
compound for the fluorous phase. It was demonstrated that there is not 
a simple relationship between the total number of fluorine atoms and 
the phase preference of molecules bearing perfluoroalkyl chains (also 
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called “fluorous ponytails”, Rfn=F(CF2)n).33 Some factors must be taken 
into account when an increased in the fluorophilicity is desired:33 
 The fluorine content. 
At least 60 wt.% fluorine is needed. It is remarkable that the 
maximum fluorine weight percentage is not 100%. For example, 
perfluorohexane has 78 wt.% fluorine. An organic molecule can 
be converted into a fluorous compound by adding fluorous 
ponytails. Moreover, a molecule is more fluorous when the 
fluorine atoms are distributed throughout the whole molecule 
rather than in one moiety.36 
 The lengths and the number of the fluorous ponytails. 
Longer fluorous chains as well as increasing the number of the 
same ponytail lead to a higher partition coefficient. 
 The molecular structure. The number of functional groups that 
may be involved in intermolecular interactions, such as 
hydrogen bonds, should be limited. However, trifluoromethyl 
substituents, either introduced as such or part of OCF3 and SCF3 
groups, are highly effective in increasing fluorophilicity. Thus, 
the trifluoromethyl group might be considered as a strong 
fluorophilic group because of its fluorine content and low 
formula weight.  
 The structure of the fluorous ponytail. Several factors, such as 
branching, hetero atoms as part of -CF2OCF2-, -CF2SCF2-, or –
CF2N(Rf)2- segments or conformational flexibility versus rigidity 
are expected to affect the fluorophilicity of a given compound.   
It is important to note that perfluoroarenes cannot be considered as 
fluorous molecules. Actually, they are more polar than 
perfluoroalkanes and tend to partition into the organic phase rather 
than the fluorous layer.  
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1.6 (Fluorinated Alkyl) Alkyl Diblocks 
 
(Fluorinated alkyl) alkyl (FnHm) diblocks are composed by a fluorinated 
moiety bound to an alkyl chain by a covalent bond. This leads to both 
steric and energetic frustrations and therefore properties of this new 
entity are different from those of the parent moieties. FnHm are 
amphiphilic (fluorinated and alkyl chains display different affinities), 
amphisteric (the two chains show different conformations, cross 
sections, and steric hindrance), and amphidynamic (they have different 
dynamic features since the fluorinated moiety is stiff, rod-like, and 
prone to aggregation while the other one is more flexible and prone to 
bend).29 Figure 1.8 illustrates the properties of linear FnHm.  
 
 
Figure 1.8 Linear FnHm diblocks are (a) amphisteric (a’: cross sections of the 
fluorinated and non-fluorinated blocks), (b) amphiphilic, and (c) 
amphidynamic.29 
 
The amphisteric, amphiphilic, and amphidynamic character of FnHm 
diblocks affects their properties. Indeed, they possess a dipole moment 
and surface activity that are essentially not observed in perfluorinated 
chains as well as in alkyl chains. In contrast to PFCs, the C-F bond 
dipoles in FnHm diblocks do not all cancel out and they are oriented 
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opposite to those of C-H bond dipoles, leading to a significant dipolar 
character.29 Due to the strongly electron-withdrawing effect of 
fluorinated chains, shift of electronic charges leading to the creation of 
an electric dipole is observed at their junction with the alkyl chains. The 
terminal CH3 and CF3 groups of the FnHm diblocks also take part to 
dipoles. The total moment dipole of the molecule is not aligned with the 
axis of the molecule since the axes of CH3 and CF3 groups form an angle 
with the axis of the FnHm diblocks, as illustrated in Figure 1.9. 
 
 
Figure 1.9 FnHm diblocks host a strong dipole (a), with components arising 
from (b) the Fn-Hm junction, (c) the terminal CF3, and (d), to a much lesser 
extent, the terminal CH3.29 
 
Since FnHm diblocks are fluorophilic (and lipophobic) at one end and 
lipophilic (and fluorophobic) at the other one, they show an 
amphiphilic character. It is remarkable the absence of a hydrophilic 
moiety in contrast to conventional surfactants. Because of their 
combined amphisteric, amphiphilic, and amphidynamic character, FnHm 
diblock molecules are used to prepare self-assembled colloids such as 
Langmuir monolayer, bilayer membranes, vesicles as well as micelles 
when the surfactant concentration exceeds the critical micelle 
concentration (CMC). 
 
1.7 Fluorine in Medicinal Chemistry 
 
The introduction of fluorine substituents into a molecule affects its 
physical and chemical properties deeply and, thus, its biological 
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activities. Actually, absorption, distribution, interaction with biological 
targets as well as metabolism and elimination of a drug are modified by 
the introduction of fluorine atoms. 
Fluorine atoms are introduced in pharmaceuticals mainly for three 
topics: 
1. Increase the metabolic stability. 
Hepatic enzymes, especially P450 cytochromes, oxidize 
lipophilic drugs limiting their bioavailability. In order to increase 
the bioavailability of pharmaceuticals, metabolic sites can be 
blocked by introducing fluorine substituents. It is important to 
verify that the introduction of a new group does not affect the 
binding with the molecular target and thus the biological activity 
of the molecule. For example, the cholesterol-absorption 
inhibitor ezetimibe was obtained starting from the lead SCH 
48461 by introducing two fluorine atoms on aromatic rings 
(Figure 1.10).37,38 These modifications block the oxidation of the 
phenyl ring to phenol as well as the dealkylation of the methoxy 
group. 
 
 
Figure 1.10 Development of ezetimibe by lead optimization of SCH 
48461. 
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Another example supporting the strong impact of fluorine atoms 
on metabolic stability of drugs is represented by the selective 
cyclooxygenase II (COX-II) inhibitor celecoxib.39,40 It was 
discovered replacing a fluorine atom of the lead compound by a 
methyl group. This reduced the very high half-life to a more 
acceptable value (Figure 1.11). 
 
 
Figure 1.11 Development of celecoxib.40 
 
It is noteworthy that in some cases the introduction of fluorine 
atoms does not prevent the oxidative metabolism.41 This is 
observed in phenyl rings bearing a nitrogen substituent in the 
para position to the fluorine substituent. In fact, a rearrangement 
takes place during metabolic oxidation and fluorine moves to an 
adjacent carbon atom. The corresponding phenol metabolite in 
para position to the nitrogen substituent is observed. 
2. Modify physicochemical properties (acidity/basicity and 
molecular lipophilicity) that affect the membrane permeability 
and therefore the drug bioavailability. 
The introduction of fluorine atoms changes the acidity or the 
basicity of neighboring ionizable functional groups and therefore 
the absorption properties of the drug are affected. For example, a 
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basic group can be required for interacting with a biological 
target, but at the same time, this basic function can also be 
responsible for the limited ability of the drug to pass throughout 
the cell membranes, leading to a low bioavailability. Van Niel et 
al. demonstrated that the introduction of fluorines in the 
serotonin 5-HT1D agonist indole-derivatives reduces the pKa of 
these compounds significantly.42 The reduction of basicity was 
found to facilitate absorption, especially for oral drug 
administration. However, the decreased basicity lowered the 
affinity of these compounds for the receptor (Table 1.6). 
 
X Y log P 
log D 
(pH=7.4) 
pKa IC50 EC50 
H H 4.97 2.34 9.7 0.3 nM 0.6 nM 
very low 
bioavailability 
F H 4.63 3.25 8.7 0.9 nM 0.9 nM 
moderate 
bioavailability 
F F 4.89 4.80 6.7 78 nM Affinity 
decreased due to 
lowering of pKa 
Table 1.6 Influence of fluorine atoms on the pKa, on the bioavailability and on 
the receptor binding for a set of 5-HT1D agonists.42 The nonfluorinated 
molecule is a very potent receptor ligand with a very low bioavailability. The 
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monofluorinated derivative has a lower pKa and is able to bind the target, 
resulting in a compound of increased bioavailability. The difluorinated 
derivative, however, is no longer basic enough to achieve high binding affinity 
for the 5-HT1D receptor. 
 
Absorption and distribution are also controlled by the balance of 
lipophilicity and hydrophilicity in a drug. Lipophilicity is often 
required to reach a good binding affinity with the target.43 
However, a high lipophilicity results in a reduced solubility in 
polar, aqueous medium. A measure for the lipophilicity of a 
molecule is the logarithmic coefficient (logD) for distribution (D) 
of a compound between octanol and water at pH 7.4. 
Replacement of hydrogen by fluorine leads to a more lipophilic 
compound. The logD of 293 compounds has been evaluated in 
order to investigate the effect of the replacement of hydrogens by 
fluorines on the lipophobicity.44 The histogram of changes in 
logD upon one H/F exchange is represented in Figure 1.12.  
 
 
Figure 1.12 Histogram of changes in logD observed upon substitution 
of a hydrogen by a fluorine.44  
 
The plot shows a Gaussian distribution in which the substitution 
of just one hydrogen by fluorine increases the lipophilicity of 
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about 0.25 log units. It is noteworthy that the tail of the Gaussian 
curve extends below zero. This means that there are few cases in 
which the replacement of a hydrogen with a fluorine decreases 
the lipophilicity. This was observed in molecules bearing an 
oxygen close to the fluorine atom. It was found that the 
lipophilicity decrease occurs when the O··· F distance of at least 
one low-energy conformer in a molecule is smaller than 3.1 Å, 
and this might be explained by solvation effects. 
3. Increase the binding affinity of a drug. 
Due to the difference in size and electronegativity between 
hydrogen and fluorine atoms, the replacement of hydrogens by 
fluorines may modify the molecular conformation and therefore 
the affinity for the biological target. For example, methoxy 
groups bound to a phenyl ring without orto substituents favor a 
planar conformation and lie on the plane of the ring.45 In 
contrast, trifluoromethoxy groups bound to a phenyl ring 
without orto substituents tend to turn out of plane because of 
their larger size. For that reason, trifluoromethoxy substituent is 
not an isosteric replacement of methoxy group since it adopts a 
different conformation. Because of the polarized nature of C-F 
bond, C-F can interact with a biological target mainly through 
electrostatic interactions, such as dipole-dipole and charge-
dipole interactions. However, these intermolecular electrostatic 
interactions are weak,46 in contrast to intramolecular electrostatic 
interactions which are stronger. Electrostatic interactions are 
pronounced when substituents close to the C-F bond bear a 
formal charge. For example, the gauche conformers of the 2-
fluoroethylammonium ion and the protonated 2-fluoroethanol 
are preferred because these keep the partially-negative fluorine 
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atoms close to the formally positively-charged nitrogen or 
oxygen (Figure 1.13). 
 
 
Figure 1.13 Conformations of 2-fluoroethylammonium ion and 
protonated 2-fluoroethanol.46 
 
It is more interesting to note how hyperconjugation can affect the 
preferred conformation of a fluorinated molecule. For example, 
there are two possible conformers for 1,2-difluoroethane, where 
the fluorine atoms are either gauche or anti. It was demonstrated 
by NMR and molecular modelling studies that the gauche 
conformer is more stable, showing a reduction in energy than the 
anti conformer. This result may be unexpected because of the 
steric repulsion of fluorine atoms in the gauche conformer 
(Figure 1.14). 
 
Figure 1.14 Hyperconjugation effect.46 
 
In the gauche conformer of compound 1 (Figure 1.14), both σ*CF 
orbitals are aligned with adjacent C-H bonds. Consequently, C-H 
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bonds can donate electron density into the σ*CF orbitals. This 
process is called hyperconjugation. The electron density 
donation into an antibonding orbital is equivalent to a partial 
break of the bond and for that reason the C-F bonds of 
compound 1 becomes longer and partially lose their covalent 
character. Nevertheless, the bonds are still strong because the 
fluorine atoms are now more negative and consequently are 
more strongly attracted to the partially-positive carbon atoms. As 
a result, hyperconjugation is a stabilizing effect that lowers the 
energy of the gauche conformer of compound 1. In the anti 
conformer of compound 1, each σ*CF orbital is aligned with an 
adjacent C-F bond, which is polarized and less electron donor 
than a C-H bond and then hyperconjugation is not observed. The 
gauche effect is also found in molecules containing F-C-C-O and 
F-C-C-N (compounds 2-5, Figure 1.14). Typically, the more 
electronegative substituents are, the stronger the gauche effect is. 
Hyperconjugation can also be observed with lone pairs or π-
systems as electron donors. In each case, the favored 
conformation shows the electron-donating group aligns with the 
σ*CF orbital (Figure 1.15). 
 
Figure 1.15 Conformations of 2-fluorotetrahydro-2H-pyran.46 
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An example of the F-C-C-O gauche effect and its influence on the 
biological active conformation is provided by fluorinated 
analogues of indinavir, an HIV protease inhibitor. X-ray 
crystallography showed that indinavir binds to HIV protease 
with the central carbon chain. Structure-activity relationship 
(SAR) study led to the synthesis of fluorinated analogues 1 and 2, 
as shown in Figure 1.16. Compound 1 was found to be 
equipotent with indinavir, while compound 2 was 14-fold less 
potent. This different potency might be explained with the F-C-
C-O gauche effect, which reinforces (compound 1) or destabilizes 
(compound 2) the bioactive conformation of the carbon chain. 
 
 
 
Figure 1.16 HIV protease inhibitor indinavir and its fluorinated 
analogues 1 and 2.46  
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1.7.1 Bioisosterism 
 
Bioisosterism is defined as the ability of atoms or functional groups 
with similar sizes or shapes to be interchanged without substantially 
altering biological behavior such as binding affinity.45 Fluorine can 
sterically mimic a hydrogen and stereoelectronically mimic a hydroxyl 
group.1 Fluorovinyl group (C=CHF) represents a nonhydrolyzable 
isostere of the peptidic bond, which can be used as peptidomimetic 
moiety for the design of protease inhibitors. The fluorine atom of 
fluorovinyl group takes the position of the oxygen of the carbonyl 
group of the peptide bond while the planarity of the vinyl group 
ensures a good match in size and geometry. Indeed, the double bond 
provides a good mimic of bond length and bond angles of the peptidic 
unit while its rigidity permits the control of the cis/trans conformation 
of the peptidic bond. Trifluoroethylamines are metabolically stable 
isosteres of amides. In fact, the trifluoromethyl group can mimic the 
carbonyl function of the amide, leading to a stable, nonbasic amine. 
Fluoro-C-glycosides, difluorodisaccharides, and fluorophosphonates 
can be applied as stable, nonhydrolyzable replacements for 
disaccharides, phosphates, sulfates. Figure 1.17 resumes the fluorinated 
mimics of some functional groups.    
 
 
Figure 1.17 Fluorinated mimics of some functional groups.1 
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1.8 Biomedical Applications of Perfluorocarbons 
 
The unique properties of PFCs allow the application of these molecules 
to biological and medical fields. In the following section the 
biocompatibility of perfluorocarbons as well as their biomedical 
applications will be discussed. 
 
1.8.1 Biocompatibility of Perfluorocarbons 
 
The biocompatibility of fluorocarbons is well-known. Perfluorinated 
saturated hydrocarbons with little amphiphilic character for in vivo 
applications seem to be harmless and physiologically inactive, although 
macrophage activation and flu-like symptoms might be observed.47 
Fluorocarbons injected intravenously are opsonized and phagocytosed 
by monocytes and macrophages of the reticuloendothelial system and 
stored temporarily in the liver, spleen and bone marrow.48,49 They 
diffuse throughout the cell membrane to reach the bloodstream, are 
taken up by lipid carriers, brought to the lungs and eventually excreted 
unmodified with expired air.47 It is remarkable that the strong C-F 
bonds are resistant to enzymatic metabolism. Typically, half-lives of 
PFCs range from days to week.47 The introduction of a fluorinated 
chain to a molecule usually reduces both hemolytic activity and 
toxicity.29,50 However, compounds in which short alkyl chains are 
bound to a branched fluorinated moiety show high inhalation toxicity 
due to their increased susceptibility to nucleophilic attack.29 Some 
fluorous surfactants such as perfluorooctane sulfonate (PFOS) and 
perfluorooctanoic acid (PFOA) are resistant to degradation and toxic. 
Actually, they can lead to hepatotoxicity, immunotoxicity, 
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developmental toxicity, and can also have effects on thyroid 
hormones.51 PFCs tend to bioaccumulate because of their lipophobic 
nature that makes biological recognition and elimination difficult. 
Bioaccumulation is an important issue since toxicological tissue and 
organ residual concentrations might be reached in animals as well as in 
humans.52 Unlike organochlorines, PFCs accumulate mainly in blood, 
liver, kidney, and gallbladder and show high affinity for blood proteins, 
especially albumin.53,54 In particular, perfluorinated surfactants are 
expected to bind blood and liver proteins due to their ionic character 
and enter the enterohepatic circulation.55  
 
1.8.2 Fluorous Molecules as Artificial Blood Substitutes 
 
The first biomedical application has been as artificial blood substitutes. 
Liquid fluorocarbons show low cohesive energy density and are able to 
dissolve gases with similar cohesive energy density such as O2 and CO2, 
as demonstrated by their Hildebrand parameters. As a result, PFCs can 
act as liquid carriers of oxygen with several applications, for example 
temporary blood substitutes as well as oxygenation liquids for tissues 
during organ transplantations or in ocular surgery.1 Perfluorooctyl 
bromide (PFOB) has been studied to treat respiratory distress 
syndrome.56,57 PFOB can be instilled neat into the patient’s lungs in 
order to reduce the gas-liquid interface as well as the alveolar surface 
tension. PFOB can also improve lung oxygenation in patients with 
severe respiratory failure because of its ability to dissolve O2.58 PFOB 
has been investigated as a blood substitute used as fluorocarbon-in-
water emulsion.57,59 For example, Oxygent is a lecithin-stabilized 
emulsion of PFOB able to deliver O2 to tissues. However, FDA did not 
approved Oxygent for human use since it showed an increase in 
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incidence of stroke among Oxygent-treated patients and for that reason 
phase 3 trials have been halted.47 
 
1.8.3 Fluorous Molecules in Imaging 
 
Ultrasound imaging technique is easier than other ones such as MRI 
and PET. However, it requires efficient contrast agents to highlight the 
difference between tissues.1 The contrast agents used in ultrasound 
imaging are micron-size gas bubble products that are injected into the 
bloodstream. Gas bubbles can reflect sound waves more effectively 
than red blood cells, providing a bright contrast. The unique properties 
of PFCs (very low water solubility, high vapor pressure relative to 
molecular weight, and biological inertness) allow the application of 
these compounds as contrast agents. In fact, PFC vapor counterbalances 
the surface tension and blood pressure forces that push the gases inside 
the bubbles toward dissolution. Typically, the bubble wall is made up 
of phospholipids, proteins or biodegradable synthetic polymers. PFCs 
used as contrast agents are formulated as emulsions. 
 
PFCs are also being investigated for magnetic resonance imaging (MRI) 
applications. 19F atom has a nuclear spin of ½ and a high gyromagnetic 
ratio, which means that this isotope is very responsive to MRI 
measurements. Furthermore, it has a 100% natural abundance. Since 
there is no fluorine naturally occurring in biological tissue, any 
exogenous fluorine can be detected.60 In combination with gadolinium 
contrast agent, fluorocarbons have been applied in cardiovascular MRI 
to detect angiogenesis in sclerotic aortic valves or quantify 
atherosclerotic lesions.61,62 
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Another non-invasive technique is represented by positron emission 
tomography (PET).63 The isotope fluorine-18 has a half-life of 109 
minutes and decays by positron emission. Therefore, molecules 
containing this isotope can be taken into account for PET. This 
technique provides functional or metabolic evaluation of normal tissue 
or disease conditions and its role in cancer radiotherapy planning is 
relevant. There are several fluorinated radiotracer, for example 2-18F-
fluoro-2,2-deoxy-D-glucose (18FDG), fluorinated nucleosides, 
fluorinated aminoacids (18F-fluoroethyl-L-tyrosine (FET), 18F-
fluorothymidine (FLT), 18F-fluoro-α-methyltyrosine (FMT)), as well as 
fluorinated peptides. In particular, 18FDG is largely used in oncology.63 
18FDG is a fluorinated analog of glucose which can be taken by cell in a 
similar way than glucose, phosphorylated by hexokinase to give 18FDG-
6-phosphate but cannot undergo glycolysis. Uptake of fluorine-18 
provides a direct measure of the rate of glucose metabolism in the part 
of the body under study. 18FDG is the most applied radiolabel in PET 
because of: 
 increased glucose metabolism in tumors; 
 low positron energy with high abundance (96%) and a path 
length in tissue of approximately 0.1-0.2 cm; 
 long half-time of the isotope (109 minutes), allowing complex 
imaging studies such as dynamic studies and investigations of 
slow metabolic processes; 
 good efficacy; 
 safety, due to the low emitting energy that represents a minimal 
risk for the patient. 
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1.8.4 Fluorocarbons in Drug and Gene Delivery 
 
Due to their physicochemical properties, PFCs have been investigated 
for pulmonary drug delivery.64 In fact, they can distribute 
homogeneously throughout the lungs because of their low viscosity 
and low surface tension. However, drugs are poor-soluble in PFCs. In 
order to overcome this issue, different approaches have been 
investigated. Among them, fluorocarbon-based nanoemulsions have 
been prepared.15 In this system, the hydrophobic drug is dissolved in 
the lipid surfactants and the colloid is stabilized by the fluorocarbon. 
Fluorocarbon-based emulsions were studied to inject volatile 
anesthetics into the bloodstream. The advantage is that the onset of the 
anesthesia is more rapid because the intravenous delivery of volatile 
anesthetics eliminates the time the volatile anesthetic needs to 
equilibrate with the lungs.65 
A new class of hemifluorinated dibranched amphiphiles characterized 
by a fluorophilic (fluorous chain), lipophilic (alkyl chain), and 
hydrophilic (polar head) moieties has been synthetized.66 The 
fluorinated surfactants were able to stabilize nanoemulsions containing 
20% of the volatile anesthetic sevofluorane and 10% of the FDA-
approved PFOB to slow ripening. In one case, the surfactant was able to 
dramatically slow the ripening and stabilize the nanoemulsion for over 
1 year. This suggests their potential for clinical use. 
Due to the ability of amphiphilic fluorinated polymers to self-assemble 
into stable micelles, these molecules have been taken into account to 
encapsulate and deliver hydrophobic anticancer agents. For example, 
fluorinated amphiphilic copolymers bearing a hydrophilic block, 
represented by a PEG-polyaspartamide unit, and a fluorocarbon-
containing side-chain were synthesized and used to prepare flutamide-
32 
 
loaded micelles.67 It was demonstrated that micelles were able to 
successfully deliver the anticancer agent flutamide to cells in vitro. In 
this colloidal system, the fluorocarbon moiety is not involved in the 
encapsulation of the hydrophobic drug but rather stabilizes the 
aggregate by the fluorophobic effect. 
Hyperthermia has been recently investigated as an adjuvant treatment 
to traditional therapies with anticancer drugs based on 
thermoresponsive molecules.68 It has been demonstrated that the local 
application of heat can sensitize tumors to chemotherapy, radiotherapy 
and immunotherapy. Several mechanisms of antitumor activity are 
induced by local hyperthermia, such as loss of membrane integrity, 
upregulation of heat shock proteins, activation of immune cells and 
necrotic cell death. Since highly-fluorinated compounds show excellent 
thermomorphic properties, undergo temperature-dependent miscibility 
with aqueous environments and are biocompatible, they have been 
taken into account to combine conventional chemotherapy with local 
hyperthermia.68 For example, the alkylating agent chlorambucil was 
bound to perfluoroalkyl chains using an ester linkage as a cleavable 
site. These compounds were tested in various cancer cell lines both 
under normal conditions (37 °C) and under mild hyperthermia (42 °C).  
It was demonstrated that these molecules were more cytotoxic when 
local hyperthermia was applied. Moreover, these results were also 
confirmed in mice. Analogues bearing the hydrocarbon chain instead of 
the fluorous chain did not show thermoresponsive behavior. The 
mechanism of cell death induced by these molecules was the same as 
chlorambucil since it involved DNA damage. The mechanism of 
thermal activation might involve both the increased solubility at the 
tumor site under hyperthermia and the hydrolysis of the ester linker, 
leading to the release of the fluorinated chain. Anticancer agents in 
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which the fluorous chain was covalently linked to the drug by non-
cleavable moieties did not exhibit such extensive thermoresponsive 
activity. 
 
Perfluorinated molecules have also been investigated for gene 
delivery.69,70 Due to their hydrophobic and lipophobic character, 
perfluorinated compounds are able to improve the affinity of cationic 
polymers to cell membrane and across its lipidic bilayer. Moreover, the 
low surface energy allows perfluorocarbon molecules to strongly 
interact each other at low concentrations. This permits the formation of 
polyplexes with nucleic acid at low nitrogen to phosphorous ratio (N/P 
ratio), needed to minimize the toxicity on the transfected cells.71 
Fluorinated dendrimers characterized by excellent transfection efficacy 
and low cytotoxicity were synthetized. It was demonstrated that the 
fluorinated moiety plays a relevant role since fluorination on 
dendrimers enhances cellular uptake, endosomal escape, serum 
resistance of dendrimer/DNA polyplexes as well as modulates the 
DNA packing/unpacking ability of dendrimers.71  
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2.1 Proteomics Approaches in Drug Discovery 
 
Chemical proteomics is an emerging research field that integrates 
biochemistry, cell biology, organic synthesis, mass spectrometry and 
bioinformatics analysis.1,2 It is involved in both investigation and 
characterization of drug-target interactions in samples from cell lines or 
tissues.1 Despite several experimental procedures are employed by chemical 
proteomics, two techniques are more common:3 
 activity-based probe profiling (ABPP), which focuses on the enzymatic 
activity of specific classes of proteins 
 compound-centric chemical proteomics (CCCP), which investigates 
drug-target interactions and therefore the molecular mechanism of 
action of bioactive small molecules. 
Figure 2.1 compares these two approaches. 
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Figure 2.1 Comparison of activity-based probe profiling (ABPP) and compound-
centric chemical proteomics (CCCP).2  
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ABPP approach involves small-molecular probes composed by three 
different moieties: 
 a reactive group 
 a tag 
 a linker 
The reactive group should be able to covalently bind the active catalytic site 
of the target protein as well as be inert towards other species present in the 
biological sample. Two general classes of reactive groups can be 
distinguished: 
 electrophilic groups that bind nucleophilic active site of the target 
protein 
 photoreactive groups that label residue of the target protein following 
UV irradiation. 
ABPP probes also show a tag involved in target characterization. Indeed, the 
tag must strongly bind the resin during affinity purification step, allowing a 
quick isolation of the target protein. Biotin is widely used as tag, since it can 
strongly interact with immobilized streptavidin. Noteworthy, if the active 
probe must be modified to allow the immobilization on the stationary phase, 
the modified compound should be tested with an appropriate biological 
assay to demonstrate the activity is retained.  
The reactive group and the tag are connected by a linker which acts as a 
spacer. This avoids steric hindrance that would prevent the interaction 
between the reactive group and the target protein as well as the bound of the 
tag to the resin. Hydrophilic spacers – such as diethylene glycol – are widely 
used as linker, while hydrophobic alkyl chains might promote non-specific 
binding of proteins and therefore increase the complexity of the collected 
sample. Actually, the elution of proteins that unspecifically interact with the 
stationary phase during affinity purification complicates the sample analysis. 
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Therefore, cleavable linkers were designed, allowing the release of only 
proteins bound to the probe, while proteins that non-specifically bound to 
the resin remain anchored to the stationary phase. Cleavable linkers 
commonly used for drug discovery show acylhydrazone unit (that can be 
cleaved by hydrazides),4 peptide spacer (cleavable by proteolysis approach),5 
acid-labile groups,6 and the photolabile 1-(2-nitrophenyl)ethyl moiety.7,8 In 
ABPP technique, the cell lysate is incubated with the probe and the captured 
proteins are purified by affinity chromatography and then digested with 
trypsin. The peptides are identified by LC-MS/MS and bioinformatics 
analysis.1,3 
In contrast to ABPP, CCCP approach is more focused on target discovery. In 
this technique, a bioactive compound is immobilized on an inert and 
biocompatible matrix without loss of biological activity. The cell lysate is 
incubated with the affinity matrix and the proteins of interest are selectively 
eluted. These proteins can be either purified by SDS-PAGE before digestion 
or processed in a gel-free method (shotgun proteomics). After proteins 
digestion with trypsin, peptides are analyzed by LC-MS/MS and 
bioinformatics analysis.2,3  
Chemical proteomics approaches have several advantages.2,3 First, chemical 
proteomics is useful to study previously uncharacterized proteins by means 
of drug-target interactions. Moreover, this approach can be applied to the 
whole proteome or sub-proteomes as well as to recombinant proteins. This 
permits the investigation of proteins in their natural state and environment, 
including endogenous abundance levels, post-translational modifications, 
point or deletion mutants, presence of natural binding molecules such as 
proteins and nucleic acids. Furthermore, chemical proteomics can be 
performed in any cell type, tissue or species (humans, animals, plants and 
microorganisms), allowing the exploration of drug mechanisms in 
physiological and clinical samples (such as tumor tissue) or toxicity profiles 
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in healthy samples.2 Despite these advantages, chemical proteomics also 
suffers from several disadvantages. First, in order to link bioactive molecules 
on the stationary phase, a functional group (usually amines, carboxyl acids 
or hydroxyls) is required. If the active small molecule does not show the tag, 
it must be introduced without losing the bioactivity. Moreover, this 
technique should be performed under non-denaturing conditions to avoid 
proteins unfolding. This could be an issue for membrane proteins – 
especially those with several transmembrane domains – which require more 
drastic conditions in order to be extracted from intact biological membranes. 
Furthermore, proteins which are naturally abundant in the lysate, such as 
hemoglobin and albumin, show affinity for small molecules. Consequently, 
these proteins are anchored to the resin and eluted even if they are not the 
biological target. Moreover, abundant proteins are “sticky” and tend to 
unspecifically interact with the stationary phase. To identify the so-called 
background binding, a negative control is required. Controls are usually 
represented by inactive analogs of the active small molecules. Target proteins 
can be identified by comparing the proteins captured with the active 
molecule with those isolated by the negative control. Besides, the most 
common biochemical affinity-pair biotin-streptavidin is expensive and it is 
difficult to fully recover the bound target protein by elution.9 Finally, the 
biotinylated tag undergoes fragmentation during MS/MS analysis, 
complicating the tandem mass spectrometry spectral interpretation.10 
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2.2 Fluorous Interactions as New Tag for Chemical Proteomics 
 
In order to overcome the issues related to traditional chemical proteomics 
techniques, fluorous interactions were investigated as tool for proteomics 
approaches.11 It has been demonstrated that organic compounds bearing a 
perfluoroalkyl chain can be easily separated from a non-fluorinated mixture 
by solid-phase extraction (F-SPE).12 The purification of fluorinated organic 
compounds by means of F-SPE is more similar to a filtration rather than a 
chromatography and the separation is based on the presence/absence of the 
fluorinated tag instead of polarity or other molecular characteristics involved 
in traditional chromatography. 
F-SPE can be standard or reverse.13 Standard F-SPE is the most common and 
involves a fluorous solid phase – typically silica gel functionalized with 
fluorocarbon chains – and a fluorophilic, non-fluorous solvent as eluent. 
Figure 2.2 illustrates the purification of fluorinated-tagged molecules by 
standard F-SPE. 
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Figure 2.2 Purification of fluorinated molecules by standard F-SPE. The organic 
fraction is blue and the fluorous fraction is red.13 
 
The crude mixture is loaded into the fluorous silica gel and then non-
fluorinated components are eluted with a fluorophobic solvent such as 70-
80% MeOH-H2O or 80-90% DMF-H2O. 100% DMSO might be used if a 
component of the crude product is water-sensitive. During this step, 
fluorinated molecules remain anchored to the resin because of the strong, 
non-covalent fluorine-fluorine interactions between the fluorinated organic 
compounds and the fluorous stationary phase. Then, a fluorophilic solvent 
like water-free MeOH, CH3CN, THF is used to elute the fluorinated organic 
molecules. It is noteworthy that the fluorous silica gel can be washed with 
fluorophilic solvents (MeOH, THF or acetone) and reused, reducing both 
waste disposal and cost. 
Reverse F-SPE is a more recent technique in which the philicities of solid 
phase and eluent are reversed.13 Figure 2.3 illustrates the purification of 
fluorinated-tagged molecules by reverse F-SPE. 
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Figure 2.3 Purification of fluorinated molecules by reverse F-SPE. The organic 
fraction is blue and the fluorous fraction is red.13 
 
A mixture containing non-fluorous and fluorous organic compounds is 
charged onto regular silica gel. A fluorophilic solvent is used to elute the 
fluorinated component. Common fluorophilic solvents applied in this step 
are mixtures of FC-12 (perfluorohexanes) and diethyl ether as well as HFE-
7100 (perfluorobutyl methyl ether) blended with ethyl acetate, ether or 
another organic cosolvent. Then, a fluorophobic elution is achieved with 
regular solvents in order to recover the non-fluorinated fractions.  
Brittain et al. combined standard F-SPE with proteomics introducing the 
concept of “fluorous proteomics”.11 They selectively labeled a specific 
peptide class with a perfluorinated alkyl chain. The tagged peptides were 
isolated by F-SPE and analyzed by MALDI-MS or ESI-MS, as shown in 
Figure 2.4. 
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Figure 2.4 Fluorous proteomics approach used to isolate specific classes of 
peptides.11 
 
This methodology overcomes many of the limitations of classic bioaffinity-
based enrichment techniques. Indeed, fluorous proteomics allows separation 
strategies that cannot be accomplished with traditional bioaffinity pairs. 
Brittain et al. demonstrated that doubly-tagged (branched) peptides can be 
separated from singly-tagged (linear) peptides by using a fluorous 
proteomics approach while this separation cannot be achieved varying the 
number of biotin unit used as a tag.  Therefore, this methodology allows not 
only the isolation of fluorinated-tagged entities from non-fluorinated 
molecules, but also the separation of fluorinated species based on the 
features of the fluorinated tag. Furthermore, fluorous proteomics avoids 
inefficient recovery of tagged peptides and tag fragmentation during MS/MS 
analysis that occur in conventional chemical proteomics. It was 
demonstrated that fluorinated affinity labels are completely compatible with 
commercially-available software for protein identification such as MASCOT, 
providing an unequivocally identification of tagged proteins. Moreover, the 
fluorous proteomics approach is easier than the classic proteomics technique 
and is less expensive since the fluorous stationary phase can be recycled. It is 
noteworthy that solvents involved in the elution steps (water and methanol) 
do not interfere with MS/MS allowing the direct MS analysis of isolated 
peptides. Finally, unlike traditional bioaffinity reagents, fluorous proteomics 
might be directly applied to the isolation of different functional classes of 
small molecules in metabolomics studies. 
52 
 
2.3 Background and Project Aim 
 
Professor Romeo group synthesized molecules with antimalarial activity by 
applying the so-called “double drug” approach.14 It is based on the design of 
molecules showing two moieties that are able to interact with different 
targets. The synthesized compounds were characterized by primaquine, 
atovaquone, 4-aminoquinolinic core as well as statin group (β-hydroxyl-γ-
aminoacid) as potent and non-selective plasmepsin inhibitor (Figure 2.5). 
Actually, the statin would mimic the tetrahedral intermediate observed 
during the hydrolysis of the peptide bond by plasmepsin. 
 
 
Figure 2.5 Chemical structure of statin (β-hydroxyl-γ-aminoacid; IUPAC 
nomenclature: (3S,4S)-4-amino-3-hydroxy-6-methylheptanoic acid). 
 
RV97 is characterized by the primaquine core bound to a dipeptidyl unit. 
This moiety is linked to the statin – represented by Ile-Leu dipeptide 
functionalized with butyl amide – by 4,4’-oxybisbenzoic acid, an aromatic 
linker optimized previously,15 as shown in Figure 2.6. 
 
 
Figure 2.6 Chemical structure of RV97 (D10: IC50 = 400 nM; W2: IC50 = 700 nM).  
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Primaquine shows a different mechanism of action if compared to statin, 
since it is a liver schizonticide. Therefore, primaquine and statin recognize 
their different targets. It has recently been demonstrated that primaquine 
side effects might be reduced by binding the drug to a peptidyl unit.16 The 
quinolinic core promotes the membrane crossing, acting as a double-drug 
carrier. It has been demonstrated that RV97 blocks P. falciparum growth 
during the intraherythrocytic stage on both chloroquine-sensitive (D10) and 
chloroquine-resistant (W2) strains. RV97 showed an in vivo antiplasmodial 
activity comparable to that of chloroquine (ED50 = 6.11 mg/Kg) as well as a 
good inhibition of plasmepsin I, II, IV (Plm I: 110 nM; Plm II: 0.4 nM; Plm IV: 
0.5 nM). In order to reduce the molecular weight as well as the peptidic 
character of RV97, the number of aminoacids present in the molecule was 
reduced. Therefore, antimalarial agents with a simpler structure 
characterized by 4,4’-oxybisbenzoic acid core were synthesized. Table 1.2 
lists some synthesized antimalarial molecules with a simplified chemical 
structure. 
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Entry R R’ 
D10 
IC50 
(nM)a 
W2 
IC50 
(nM)a 
AN12 
  
12.97 8.46 
AN15 
  
3000 1100 
AO07 
  
5.83 2.76 
AO26 
  
0.49 0.34 
DC18 
  
2.45 3.13 
DHA   5.63 2.29 
CQ   23 410 
Table 2.1 Chemical structures of 4,4’-oxybisbenzoic acid derivatives and their 
antimalarial activities against D10 and W2 P. falciparum strains. 
aResults are the mean of two experiments performed in duplicate. 
 
The antimalarial activity of AN12 (Table 2.1) was thirty-fold higher on D10 
and eighty-fold higher on W2 strains if compared to RV97. To investigate the 
influence of the stereochemistry on the biological activity, the 
diastereoisomer of AN12 was synthesized (AN15). AN15 showed loss of 
antiplasmodial activity against both D10 and W2 P. falciparum strains. This 
suggested that the interaction with the biological target is highly specific and 
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the spatial orientation of the left-handed moiety of these antimalarial 
compounds inside the binding pocket is crucial for the antiplasmodial 
activity. Due to the promising results achieved for AN12, SAR study was 
focused on the R substituent modification, keeping the R’ function constant. 
In particular, it was observed that the replacement of leucine with isoleucine 
increased the activity on both D10 and W2 strains (AO07). The substitution 
of the linear, tertiary amine of AN12 with the cyclopentylamine group 
(AO26) further improved the biological activity. However, AO26 might be 
metabolized easily. In order to improve the metabolic stability of AO26, the 
methyl ester was replaced by a primary amide, leading to DC18. This 
molecule showed an antimalarial activity against W2 strains comparable to 
dihydroartemisinin one. Furthermore, DC18 showed a toxicity on human 
mammary epithelial cells (HMEC) in the micromolar range (IC50 > 30 μM). 
The parasitemia was decreased of 70% after 4-day intraperitoneal injection of 
DC18 to mice infected with P. vinkei. However, the parasitemia rose again 
from the fifth day of treatment. This might be explained by the metabolism of 
DC18 (microsomial clearance: 85.50 μl/min/mg). 
The above-mentioned results suggested that this new class of antiplasmodial 
compounds is effective against both D10 and W2 P. falciparum strains. 
Nevertheless, the biological target(s) of these molecules is (are) still 
unknown. The identification of the target protein(s) of these antimalarial 
agents would permit rational SAR study as well as facilitate the drug 
discovery. Moreover, the target of these compounds might be innovative, 
allowing the exploration of new strategies for malaria therapy. The 
identification of new target proteins involved in this pathology would be 
very useful to overcome the imminent problem related to the development of 
resistance to currently-used antimalarial drugs. In fact, the mortality due to 
malaria has significantly increased at the end of the last century.17 This trend 
has been associated to the development of resistance by P. falciparum against 
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quinolines, especially chloroquine.18 In order to face this problem, 
combination therapy involving artemisinin derivatives (ACT, artemisinin 
combination therapy) was tested. However, in 2006 a case of resistance to 
artemisinin has been reported in Ta Sanhal, a village near the border between 
Cambodia and Thailand. The development of resistance to artemisinin 
observed in southeast Asia is due to the massive use of ACT.19 Noteworthy, 
artemisinin and its derivatives are the most effective drugs for malaria and 
nowadays cannot be replaced by other commercially-available molecules. 
For this reason, the possibility that malarial parasites develop resistance to 
artemisinin is a problem of global health. To overcome the resistance issue, 
molecules with innovative mechanisms of action as well as active on new 
targets are strongly needed. 
To identify the biological target of the 4,4’-oxybisbenzoic acid class of 
antimalarial agents, the chemical proteomics approach described by Ki Duk 
Park has been applied (Figure 2.7).4  
 
 
Figure 2.7 Chemical proteomics approach for target identification.4 
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According to this approach, DC18 was used as active compound and it was 
modified by introducing a terminal alkyne group. The retention of the 
antimalarial activity was tested (Figure 2.8). 
 
 
Figure 2.8 Derivatized DC18 used as tag compound for target identification (D10: 
IC50 = 8 nM; W2: IC50 = 12 nM). 
 
The modified tag compound was then incubated in P. falciparum lysate to 
permit the interaction with the biological targets. By means of click chemistry 
reaction, the tag compound bound to the target proteins was captured taking 
advantage of a suitable cleavable linker. This linker was composed by a 
terminal azide, an acylhydrazone linker and a terminal biotin unit. Indeed, 
the azide was required to react with the alkyne by the click chemistry 
reaction while the biotin was involved in the affinity purification. The high 
selectivity of this approach arose from the presence of the cleavable 
acylhydrazone. In fact, an exchange acylhydrazone/acetyl hydrazide 
allowed the selective elution of the target due to the presence of the 
acylhydrazone unit only in the incubated compound while the naturally 
biotinylated proteins remained anchored to the streptavidin beads. Then, the 
eluted proteins were purified by SDS-PAGE, digested and the peptides 
analyzed by LC-MS/MS. Bioinformatics analysis afforded the primary 
structure of the isolated proteins. This approach allowed the identification of 
11 Plasmodium proteins as potential targets of DC18. The isolation of a small 
number of potential biological targets starting from a complex lysate 
underlines the effectiveness of this method. However, this traditional 
proteomics approach shows several limitations. In particular, the click 
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chemistry reaction between the tag compound – bearing the target proteins – 
and the cleavable linker would lead to the formation of a large entity. This 
might complicate the click chemistry reaction, limiting the entire chemical 
proteomics approach. Indeed, only tagged-protein captured by the cleavable 
linker can be anchored to the resin. Moreover, several steps are needed, 
making the methodology lengthy and therefore not applicable to high-
throughput screening. Furthermore, the stationary phase used to purify the 
lysate is agarose beads covalently bound to streptavidin. This resin is able to 
retain biotin-tagged proteins as well as “sticky” components, which are 
abundant in the lysate, albumin and hemoglobin among them. These 
contaminants are called background proteins and are often aspecifically 
eluted with the biological targets. This complicates the mass analysis and 
consequently the target identification. 
Therefore, a new recognition system lacking of the limitations displayed by 
biotin-streptavidin pair must be investigated. In particular, the new 
recognition system should be involved in interactions strong enough to 
apply the affinity purification. However, it must be more selective to avoid 
the aspecific binding issue and therefore facilitate the target identification. 
Moreover, the whole proteomics approach should be improved to reduce the 
number of steps involved in the methodology as well as minimize the sample 
handling that might cause loss of proteins or contaminations. 
Therefore, the project aim was designing and validating an innovative 
proteomics technique for target identification based on the strong and non 
covalent fluorous interactions. Indeed, fluorine atoms can strongly interact 
each other and therefore fluorous interactions might be considered as a new 
recognition system for chemical proteomics. This would simplify the 
proteomics approach since the click chemistry would not be required. 
Indeed, the tag compound bound to the protein might be directly anchored 
to the fluorinated stationary phase, avoiding the capture by the cleavable 
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linker. The selectivity would be ensured by the fluorous interactions between 
the resin and the tagged protein. Therefore, this new recognition system 
should be able to simplify both the synthesis and the affinity 
chromatography. 
Figure 2.9 illustrates the designed fluorous proteomics technique. 
 
Figure 2.9 Innovative fluorous proteomics approach. 
 
The fluorous proteomics approach requires the introduction of a 
perfluoroalkyl chain in a bioactive compound. Then, the fluorinated 
derivative is incubated with the lysate to permit the interaction with the 
target. The fished protein is isolated by affinity chromatography using a 
perfluorinated stationary phase and taking advantage of the strong and non-
covalent fluorous interactions. Then, the target is purified by SDS-PAGE and 
identified by LC-MS/MS. This approach overcomes some limitations of the 
traditional chemical proteomics approach: 
 The click-chemistry reaction is avoided since the fluorinated tag is 
already present in the active compound 
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 There is no need to synthesize a cleavable linker. Indeed, the selective 
elution arises from the strong fluorous interactions that can be 
overcome by a fluorophilic solvent such as methanol.  
 Only fluorinated molecules can interact with the fluorinated 
stationary phase, avoiding aspecific binding.20 This strongly reduces 
the amount of contaminants and background proteins present in the 
eluted sample that would complicate the target identification. 
 
To validate the described fluorous proteomics approach, papain was selected 
as target protein. Papain is a cysteine endopeptidase extracted from Carica 
papaya with a molecular weight of about 23,800 Dalton. It is characterized by 
a single peptide chain of 211 residues folded into two parts forming a cleft.21 
The structure is stabilized by three disulfide bonds and shows seven subsites 
able to accommodate a single amino acid residue of a peptide substrate.22 
The catalytic site is formed by the triad Cys25-His159-Asn175.23 Since papain 
is commercialized in its inactive form, it must be activated before use by 
reducing the disulfide bonds. It is irreversibly inhibited by diazomethyl 
ketones, which form a covalent bond with Cys25.23 Figure 2.10 shows the 
chemical structure of one of the diazomethyl ketone papain inhibitors 
described in the literature.23 
 
 
Figure 2.10 Chemical structure of a diazomethyl ketone inhibitor.23 
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Papain was chosen to validate the fluorous proteomics technique for several 
reasons: 
 it is a small protein with a simple structure 
 it is commercially available  
 it is not expensive 
 it shows homology with mammalian cysteine proteases involved in 
several diseases related to tissue degeneration and therefore is well 
studied24 
 its activation is completed in 45 minutes 
 diazomethyl ketones are selective papain inhibitors easy to synthesize 
 diazomethyl ketones covalently bind papain 
 its complete inhibition by diazomethyl ketones is achieved rapidly (15 
minutes) 
 
With the aim of validating the fluorous proteomics approach, the papain 
substrate 4-nitrophenyl((benzyloxy)carbonyl)glycinate and fluorinated 
diazomethyl ketone inhibitors were synthesized. Both the activation of 
papain and its inhibition were tested by UV assay. Then, the inhibited papain 
was isolated by fluorous proteomics following the procedure described 
previously (Figure 2.9). The eluted sample was analyzed by SDS-PAGE and 
mass spectrometry. 
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2.4 Synthetic Schemes 
 
2.4.1 Synthesis of Compound 2-1 
 
Scheme 2.1 shows the synthesis of compound 2-1, which acts as substrate for 
papain. 
 
 
Scheme 2.1 Synthesis of papain substrate. 
 
Compound 2-1 is achieved by esterifying Z-Gly-OH with p-nitrophenol, 
using HBTU and DMAP as coupling reagents.  
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2.4.2 Synthesis of Compound 2-2 and Compound 2-3 
 
Scheme 2.2 shows the synthesis of compounds 2-2 and 2-3. These molecules 
are fluorinated inhibitors of papain. 
 
Scheme 2.2 Synthetic scheme of compounds 2-2 and 2-3. 
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The synthesis of compounds 2-2 and 2-3 starts with a coupling reaction 
between Boc-L-Phe-OH and Gly benzyl ester using TBTU and HOBt as 
coupling reagents to give intermediate 2-6. Then, intermediate 2-6 is Boc-
deprotected before coupling with Boc-L-Leu-OH to afford intermediate 2-7, 
which is in common for the syntheses of compounds 2-2 and 2-3. Indeed, 
intermediate 2-7 is Boc-deprotected, reacted with perfluoroheptanoic acid or 
pentafluoropropionic anhydride and then deprotected by hydrogenolysis to 
give intermediate 2-8 and 2-9 respectively. Both intermediate 2-8 and 2-9 are 
reacted with diazomethane prepared previously from Diazald®, to afford 
compounds 2-2 and 2-3 respectively. The box at the top right-handed side of 
Scheme 2.2 shows the synthesis of Diazald® starting from p-toluensulfonyl 
chloride, methylamine and sodium nitrite. 
 
2.4.3 Synthesis of Compound 2-4 
 
Scheme 2.3 shows the synthesis of compound 2-4, which acts as fluorinated 
inhibitor of papain with a different chemical structure if compared to 
compounds 2-2 and 2-3. 
Intermediate 2-10 is prepared according to the general method described by 
Elshani et al, starting from 2-bromoacetic acid and 1H,1H-
pentadecafluoroheptanol.25 Intermediate 2-10 is coupled with Boc-
deprotected intermediate 2-7 to afford intermediate 2-11 with a good yield. 
For this reaction, DIC is chosen as coupling reagent. Intermediate 2-11 is then 
deprotected by hydrogenolysis and reacted with diazomethane, prepared 
previously from Diazald®, to give compound 2-4.  
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Scheme 2.3 Synthesis of compound 2-4. 
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2.4.4 Synthesis of Compound 2-5 
 
The synthesis of the compound 2-5 is shown in Scheme 2.4. 
 
 
Scheme 2.4 Synthetic scheme of compound 2-5. 
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The synthesis of compound 2-5 starts with the nucleophilic reaction between 
1H,1H-pentadecafluoroheptanol and epichlorohydrin to afford dibranched 
intermediate 2-12, which is then reacted with bromoacetic acid to give 
intermediate 2-13.  Then, intermediate 2-13 is coupled with Boc-deprotected 
intermediate 2-7 to afford intermediate 2-14 using DIC as coupling reagent. 
Intermediate 2-14 is then deprotected by hydrogenolysis and reacted with 
diazomethane, prepared previously from Diazald®, to give compound 2-5.  
 
2.5 Reactions and Mechanisms 
 
2.5.1 Coupling Reaction 
 
The generation of amide bonds is an important step for the synthesis of 
molecules of biological interest. The first step for the formation of a peptide 
bond is the activation of the carboxylic group, then the nucleophilic attack of 
the amine on an activated carboxylic acid is required. The carboxylic acid 
activation can be achieved by using the so-called coupling reagents. Notably, 
the configuration of the involved amino acids – especially when the chiral 
center is in the α-position – must be retained during the peptide synthesis, 
regardless the coupling technique used (in solution or solid-phase 
approaches). Thus, the main challenge in the peptide synthesis is the choice 
of suitable coupling reagents that must ensure the accomplishment of high 
yield as well as no racemization observed. 
The main mechanisms responsible for the racemization of α-amino acids are 
enolization and, when possible, formation and enolization of an 5(4H)-
oxazolone (oxazolonium ion for N-alkyl amino acids), as shown in Figure 
2.11.26 
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Figure 2.11 Mechanisms responsible for the racemization during peptide synthesis.26 
(Act: Activating group). 
 
The method of activation of the carboxylic group deeply affects the degree of 
racemization. The presence of a base promotes the racemization since the 
proton in the α-position can be easily removed. Moreover, if the activating 
group (Act-) is a good leaving group promoting the formation of the 5(4H)-
oxazolone, the proton in the α-position will be more acidic and therefore 
more easily removed by the base. However, the presence of a base and a 
good leaving group are often required since they lead to a better coupling 
yield. 
 
Despite several classes of coupling reagents might be distinguished, the main 
groups are represented by carbodiimides and benzotriazoles. Figure 2.12 
shows some components of each class. 
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Figure 2.12 Carbodiimides and benzotriazoles coupling reagents. 
 
Carbodiimides have been used as coupling reagents since 1955, DCC being 
the most widely employed. The mechanism of activation performed by 
carbodiimides is represented in Figure 2.13. 
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Figure 2.13 Mechanism of carboxylic acid activation observed with carbodiimides. 
 
First, a proton is transferred to the carbodiimide followed by addition of the 
carboxylic acid to give the O-acylisourea (Figure 2.13, a). This intermediate is 
highly reactive and therefore can attack the amino acid providing the 
corresponding amide (Figure 2.13, f). However, the O-acylisourea might 
rearrange to afford the corresponding N-acylurea (Figure 2.13 b), which is 
not reactive. The O-acylisourea might also react with another carboxylic acid 
group leading to the corresponding symmetric anhydride (Figure 2.13, c) 
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which is an excellent acylating agent. O-acylisourea can undergo 
intramolecular cyclization to give a 5(4H)-oxazolone if the carboxylic acid is 
a N-carboxamide or a carbamate α-amino acid (Boc, Fmoc) (Figure 2.13, d). 
The 5(4H)-oxazolone can act as acylating agent. However, it is less powerful 
than O-acylisourea or the symmetric anhydride. Moreover, tautomerization 
of O-acylisourea to give the enol form might lead to racemization. A 
nucleophilic agent, such as hydroxylamine derivative (R’R’’NOH) can react 
with the O-acylisourea, affording the corresponding active ester (Figure 2.13, 
e) which is less reactive but more stable. Notably, the solvent used for the 
coupling reaction affects the rate at which the O-acylisourea forms. When the 
activation is accomplished in a solvent with low dielectric constant (such as 
DCM), the O-acylisourea is obtained instantaneously. However, when a 
more polar solvent (such as DMF) is used, a mixture of starting amino acid, 
symmetric anhydride, N- acylurea and urea is formed. In order to reduce the 
epimerization as well as increase the yield while using carbodiimides as 
coupling reagents, the addition of HOBt as an additive may be taken into 
account.27 HOBt acts as a nucleophilic agent by reacting with the O-
acylisourea to give the corresponding active ester (Figure 2.14). 
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Figure 2.14 Mechanism of activation by HOBt when used as an additive with 
carbodiimides.27   
 
The main advantage in using this additive as trapping agents of the O-
acylisourea is its ability to increase the concentration of the active species 
when DMF is used as a solvent as well as reduce racemization of the 
carboxylic function. 
 
Another important class of coupling reagents is represented by 1-H-
benzotriazoles. Several salts are associated to this class, including uronium, 
aminium, phosphonium, immonium, and carbonium salts.27 HATU (Figure 
2.12) is the most reactive among all as well as the most expensive. The 
presence of chlorine is responsible for the greater reactivity of HCTU and 
TCTU compared to HBTU and TBTU (Figure 2.12). The chemical species that 
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react with the salt is the deprotonated carboxylic function, thus a small 
amount of a base is needed. Figure 2.15 shows the mechanism of activation 
observed with 1-H-benzotriazole-based coupling reagents. 
The acyloxy-phosphonium species cannot be isolated and therefore they 
react instantaneously with the benzotriazole derivative to afford an 
intermediate which reacts with the ilino-ammonium component leading to 
the corresponding amide.  
 
 
Figure 2.15 Mechanism of activation observed with 1-H-benzotriazole-based 
coupling reagents. 
 
2.5.2 Diazomethane and Diazomethyl Ketone Syntheses 
 
The formation of diazomethyl ketone derivatives requires the preparation of 
diazomethane first, which is immediately reacted with a carboxylic acid to 
give the corresponding diazomethyl ketone, as shown in Figure 2.16. 
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Figure 2.16 Synthesis of diazomethyl ketone derivative. 
 
Diazomethane (CH2N2) is a yellow gas at rt. It is extremely poisonous and is 
a potent carcinogen. Diazomethane is also a sensitizer and long-term, low-
level exposures can lead to asthma-like symptoms. Moreover, diazomethane 
is highly instable since it can explode if exposed to sharp surfaces or certain 
chemicals such as drying agents. Therefore, it is conserved and handled as 
diethyl ether solution to prevent accidents. Diazomethane is usually 
prepared in the exact amount needed for the synthesis of diazomethyl 
ketones, in order to avoid the storage of the remaining solution of 
diazomethane. Diazald® (N-methyl-N-nitroso-paratoluenesulfonamide) is 
usually used as precursor. Diazald® undergoes an internal rearrangement, 
then it is deprotonated by a base (such as KOH) and a dissociation leads to 
the diazomethane gas. Figure 2.17 illustrates the above-described 
mechanism. 
 
 
Figure 2.17 Mechanism of formation of diazomethane starting from Diazald®. 
 
Diazomethane bears a negative charge on the carbon, as demonstrated by its 
resonance structures (Figure 2.18). 
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Figure 2.18 Resonance structures of diazomethane. 
 
Diazomethane is largely used in organic chemistry because of its ability to 
act as methylating agent for carboxylic acids. This can be also used as 
effective way to destroy the unreacted gas. Indeed, diazomethane is 
destroyed by adding acetic acid, which acts as a scavenger leading to the 
formation of harmless methyl acetate and nitrogen gas (Figure 2.19). 
 
 
Figure 2.19 Inactivation of diazomethane by acetic acid. 
 
As mentioned before, diazomethane is the starting material to prepare 
diazomethyl ketone derivatives. The procedure involves the reaction 
between a carboxylic acid and isobutyl chloroformate, leading to an unstable 
anhydride, which cannot be isolated. This intermediate then reacted with the 
diazomethane to afford the desired diazomethyl ketones, as shown in Figure 
2.20. 
 
Figure 2.20 Mechanism of diazomethyl ketone synthesis. 
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2.5.3 Papain Inactivation by Diazomethyl Ketone Inhibitors 
 
The proposed mechanism for the inactivation of papain by diazomethyl 
ketones is shown in Figure 2.21.28  
 
 
Figure 2.21 Mechanism of papain inactivation.28 
 
The thiol group of Cys25 is part of the catalytic triad as it is transiently 
acylated during catalysis. The observation that diazomethyl ketones do not 
react with low-molecular-weight thiols, such as β-mercaptoethanol and 
cysteine, suggests that the mechanism of papain inhibition involves 
neighboring groups in the catalytic pocket, as well as the formation of a 
transient thiohemiketal, the protonation by the imidazolium ion of His159 
and the alkylation on sulphur. Notably, the atom that is protonated by the 
imidazolium ion of papain is the same as the atom that is finally bonded to 
the sulphur atom of papain. It is supposed that S-C bond formation occurs by 
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the setting-up of a three-membered cyclic transient state. Therefore, the side 
chain of His159 must be rotated to reduce the steric hindrance and therefore 
permits the catalysis. 
 
2.6 Fluorinated Papain Inhibitors 
 
In the following paragraphs, the structure of diazomethyl ketone papain 
inhibitors, the optimization of their synthesis as well as the stability of the 
obtained fluorinated molecules are discussed. 
 
2.6.1 Chemical Structure of Fluorinated Papain Inhibitors 
 
Fluorinated papain inhibitors we designed for the application of the fluorous 
proteomics approach are low-molecular-mass molecules that consist of three 
parts. One moiety is represented by a peptidyl fragment with a suitable 
sequence for the interaction with papain binding pocket. The second part is 
represented by the reactive diazomethyl ketone group, which can covalently 
bind Cys25 in the catalytic site and thus inhibit papain. The third moiety is a 
fluorinated chain responsible for the interaction with the fluorinated 
stationary phase during affinity purification. The length of the fluorous chain 
is crucial, since it is involved in the formation of the fluorous phase during 
purification. Indeed, a long fluorinated chain (C6F13) is required to allow the 
interaction with the stationary phase during affinity purification. 
Interestingly, if the fluorous alkyl chain is very long (> C8F17), the synthesis 
of these compounds becomes a challenge. This is due to the poor reactivity of 
molecules showing a high degree of fluorination and to problems concerning 
the solubility of the starting materials in the common organic solvents which 
might arise. Indeed, highly fluorinated compounds tend to segregate 
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forming the fluorous phase, making the interaction with other reactants 
difficult. However, a short chain cannot interact with the fluorinated 
stationary phase and therefore the fluorinated molecule would not be 
retained in the column during affinity chromatography. The fluorinated 
inhibitors synthesized for the fluorous proteomics approach have different 
chain length, as Figure 2.22 shows. 
 
 
Figure 2.22 Synthesized fluorinated diazomethyl ketone inhibitors. 
 
The fluorinated alkyl chain is directly bound to the peptidyl fragment in 
compounds 2-2 and 2-3 while compounds 2-4 and 2-5 show an ether bridge 
linking the two moieties. The short spacer introduced in compounds 2-4 and 
2-5 distances the fluorinated alkyl chain from the peptidyl unit, minimizing 
steric hindrance during affinity purification. Moreover, compounds 2-2, 2-3 
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and 2-4 are linear semifluorinated molecules while compound 2-5 is 
dibranched. Consequently, compound 2-5 is a doubly-tagged molecule and 
therefore can be taken into account to design innovative separation schemes. 
Actually, a mixture of linear and branched fluorinated species might be 
separated by fluorous proteomics approach because of their different 
chemical structures. 
 
2.6.2 Synthesis Optimization of Fluorination Reaction  
 
As mentioned before, compound 2-2 bears the long fluorinated alkyl chain 
directly bound to the peptidyl fragment while compound 2-4 has an ether 
spacer placed between the fluorous chain and the peptidyl unit. The absence 
of a spacer in compound 2-2 complicates the synthesis of this molecule. 
Indeed, the reactivity of fluorocarbons is greatly reduced when the fluorous 
moiety is directly bound to the reactive functional group.29 This can be 
explained taking into account the strong electron-withdrawing effect of the 
fluorous chain. Therefore, the fluorination of intermediate 2-7 was difficult 
and different reaction conditions were investigated. 
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Entry Reagents 
Reaction 
Conditions 
Yield (%) 
1 
EDAC 
DMAP 
o.n., rt 0 
2 TBTU o.n., rt 0 
3 
SOCl2 
pyridine 
1) 3 h, reflux 
2) o.n., rt 
0 
4 
DCC 
DMAP 
o.n., rt 18 
Table 2.2 Optimization of fluorination reaction of intermediate 2-7. 
 
The reaction was firstly carried out using common coupling reagents (Table 
2.2, entries 1 and 2). Since the desired product was not achieved, the 
activation of perfluoroheptanoic acid to perfluoroheptanoil chloride was 
performed (Table 2.2, entry 3) without good results. Fluorination reaction 
was successful only using DCC as coupling reagent (Table 2.2, entry 4). 
In contrast, intermediate 2-11 was achieved with a good yield (55%) and 
therefore the optimization of the reaction conditions was not required. In 
fact, the presence of the ether linker separates the fluorinated alkyl chain 
from the reactive carboxylic group in intermediate 2-10, shielding the 
electron withdrawing effect of fluorine atoms and therefore promoting the 
coupling with the peptidyl fragment (Boc-deprotected intermediate 2-7) to 
afford intermediate 2-11.  
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2.6.3 Stability of Highly Fluorinated Intermediate 2-8 
 
Since the introduction of a perfluorinated alkyl chain deeply modifies the 
chemical properties of the whole molecule, we wondered if fluorinated 
inhibitors were stable in the aqueous buffer used to perform the fluorous 
proteomics approach. We reasoned that the perfluorinated alkyl chain 
directly bound to the peptidyl fragment by amide bond – as in compound 2-2 
– might show a strong electron-withdrawing effect, making the amide bond 
labile and therefore easy to hydrolyze. Consequently, the fluorinated chain 
might be lost, compromising the fluorous proteomics study. In contrast, the 
presence of a perfluorinated alkyl chain might protect the amide bond from 
the hydrolysis because of steric hindrance arising from fluorine atoms that 
might mask the amide bond. These hypotheses led us to test the stability of 
highly fluorinated molecules in the aqueous buffer. The medium chosen for 
this test is the same used to activate papain before performing the fluorous 
proteomics approach. It is an aqueous phosphate buffer (pH=6.5) containing 
β-mercaptoethanol – as reducing agent able to reduce papain disulfide bonds 
– and EDTA – as chelating agent. Notably, the diazomethyl ketone group 
does not react with β-mercaptoethanol, as reported in the literature.30 
Moreover, it is stable at pH=6.5. 
Therefore, we synthesized intermediate 2-8 and tested its stability in the 
phosphate buffer before moving on the more tedious synthesis of compound 
2-2. With this aim, a solution of intermediate 2-8 in DMF was mixed with the 
buffer and then vigorously shaken at rt, reproducing the same conditions 
performed for papain inhibition. Then, the mixture was extracted with DCM 
to allow the separation of intermediate 2-8 from inorganic salts. The organic 
phase was dried over MgSO4, filtered and concentrated under reduced 
pressure. The obtained residue was then analyzed by mass spectrometry. 
Figure 2.23 shows the mass spectrum of this residue. 
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Figure 2.23 Mass spectrum of intermediate 2-8 after incubation in the aqueous 
buffer. Calculated m/z: 681.15. Found m/z: 682.13 [M+H]+; 703.95 [M+Na]+. 
 
The mass spectrum showed the molecular peak of intermediate 2-8, 
suggesting that this molecule is stable under incubation conditions. 
83 
 
2.7 UV Spectroscopy Studies 
 
The activation of papain as well as its inhibition by diazomethyl ketone 
derivative was tested by UV spectroscopy assays, as described in the 
following paragraphs. 
 
2.7.1 Papain Activation Assay 
 
Since papain is commercialized in an inactive and more stable form, it must 
be activated before use by reducing disulfide bonds. Papain activation was 
carried out by incubating the protein for 1 hour at rt in phosphate buffer 
(pH=6.5) containing β-mercaptoethanol and EDTA. The actual protein 
activation was demonstrated by UV spectroscopy, taking advantage of the 
ability of papain to hydrolyze 4-nitrophenyl((benzyloxy)carbonyl)glycinate 
(compound 2-1). UV assay was performed at 340 nm since the absorption of 
4-nitrophenol does not depend on pH at this wavelength. Figure 2.24 
illustrates the hydrolysis of compound 2-1. 
 
 
Figure 2.24 Hydrolysis of compound 2-1. 
 
The entity of spontaneous hydrolysis of compound 2-1 in the aqueous 
medium was also evaluated. Spontaneous hydrolysis of compound 2-1 was 
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monitored for 25 minutes both at rt and at 0 °C. As expected, spontaneous 
hydrolysis was greater at rt (Figure 2.25). 
 
 
 
Figure 2.25 UV spectrum of spontaneous hydrolysis of compound 2-1 carried out at 
rt (blue curve) and at 0 °C (red curve). 
 
Then, a new experiment was set up to evaluate the enzymatic activity of 
papain taking into account the spontaneous hydrolysis of compound 2-1 
(Figure 2.26). 
 
Blue curve: room temperature Red curve: 0 °C 
Reference: buffer w/o papain Reference: buffer w/o papain 
Sample: buffer w/o papain + 
compound 2-1 (2.5 * 10-5) 
Sample: buffer w/o papain + 
compound 2-1 (2.5 * 10-5) 
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Figure 2.26 Enzymatic activity of papain taking into account the spontaneous 
hydrolysis of compound 2-1. Blue curve was obtained at rt while red curve at 0 °C. 
 
As shown in Figure 2.26, red and blue curves reached the plateau after 10 
and 15 minutes respectively. As expected, the enzymatic activity is greater at 
rt than at 0 °C. 
 
These experiments demonstrated papain activation under the previously 
described incubation conditions.  
 
2.7.2 Papain Inhibition Assay 
 
The ability of diazomethyl ketones to inhibit cysteine proteases like papain 
has already been described in the literature. However, the modification of the 
inhibitor by introducing a fluorinated alkyl chain leads to a new entity whose 
Blue curve: room temperature Red curve: 0 °C 
Reference: buffer w/o papain + 
compound 2-1 (2.5 * 10-5) 
Reference: buffer w/o papain + 
compound 2-1 (2.5 * 10-5) 
Sample: buffer with papain (1.45 * 10-5 M) + 
compound 2-1 (2.5 * 10-5) 
Sample: buffer with papain (1.45 * 10-5 M) + 
compound 2-1 (2.5 * 10-5) 
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ability to inactivate papain must be proved. Papain inactivation performed 
by fluorinated diazomethyl ketone derivative was tested before carrying out 
the fluorous proteomics approach. Indeed, papain inhibition arises from the 
alkylation of Cys25 in the catalytic site by the diazomethyl ketone derivative 
and therefore the inhibitor is covalently bound to the protein. Consequently, 
the success of the fluorinated proteomics approach depends mainly on 
fluorine-fluorine interactions between the fluorous alkyl chain borne by the 
inhibited papain and the fluorinated stationary phase. 
To verify the papain inhibition, compound 2-2 was taken into account to 
perform UV spectroscopy assay. After papain activation, compound 2-2 was 
incubated with the buffer solution of the enzyme at rt for 15 minutes, 
keeping the solution vigorously shaken. Noteworthy, the purification of the 
activated papain is not required. Actually, diazomethyl ketones do not react 
with low-molecular-weight thiols and therefore β-mercaptoethanol does not 
affect the ability of diazomethyl ketone to bind papain.28,31 Moreover, the 
presence of β-mercaptoethanol might be helpful, since it keeps the papain in 
the active form. 
As shown in Figure 2.27, compound 2-2 was actually able to inhibit papain. 
In fact, the inhibition curve was flat, meaning that the hydrolysis of 
compound 2-1 catalyzed by papain did not occur.  
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 Reference: buffer containing papain (1.45 * 10-5) + compound 2-1 (4.4 * 10-3) 
 Sample: buffer containing papain (1.45 * 10-5) + compound 2-1 (4.4 * 10-3) + 
  compound 2-2 (4.4 * 10-3) 
Figure 2.27 UV spectrum of papain inhibition. 
 
2.8 Fluorous Proteomics Study 
 
2.8.1 Affinity Purification 
 
Affinity purification allows the separation of non-fluorinated components 
from fluorinated species, inhibited papain among them. First, a fluorophobic 
washing carried out with water is required to elute non-fluorinated 
molecules, such as salts as well as the fraction of papain that did not react 
with the fluorinated inhibitor and therefore was not retained in the column. 
The following fluorophilic elution performed with methanol allows the 
collection of fluorinated components, which were able to anchor the 
stationary phase. Then, the resin is recycled by washing with acetone. It is 
crucial to investigate how many column volumes of solvents are needed to 
completely elute non-fluorinated and fluorinated species. With this aim, 
λ = 340 nm 
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affinity chromatography of non-inhibited papain as well as papain inhibited 
by compound 2-4 was performed. In particular, 5 column volumes of water 
and 5 more of methanol were collected. These samples were reacted with 
Coomassie Brilliant Blue dye and then analyzed by UV assay. Indeed, 
Coomassie Brilliant Blue binds to proteins through ionic interactions 
between dye sulfonic acid groups and positive protein amide functions as 
well as through van der Waals interactions. Under acidic conditions, the dye 
has a brownish color, which turns blue when it is bound to the protein. The 
optical absorbance of the protein-bound dye is measured at a wavelength of 
595 nm. 
Figure 2.28 and Figure 2.29 show the absorbance values of the elution with 
water and methanol for non-inhibited and inhibited papain respectively. 
 
 
Figure 2.28 Plot absorbance value over column volume for non-inhibited papain 
(green line: elution with water; red line: elution with methanol). 
λ = 595 nm 
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Figure 2.29 Plot absorbance value over column volume for inhibited papain (green 
line: elution with water; red line: elution with methanol). 
 
Focusing on the fluorophobic elution for non-inhibited and inhibited papain 
(Figure 2.30), it is evident that papain was almost completely collected 
within two column volumes for the inhibited sample (Figure 2.30, orange 
curve). Indeed, the absorbance reduced after the elution with two column 
volumes of water, keeping the curve almost flat. 
Despite the protein was collected mainly within two column volumes for the 
non-inhibited sample, it kept to be eluted in the following fluorophobic 
elutions (Figure 2.30, blue curve). 
 
λ = 595 nm 
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Figure 2.30 Comparison of water elutions for non-inhibited and inhibited papain. 
 
 
As expected, the results obtained for the washings with methanol were 
different for the non-inhibited and the inhibited samples (Figure 2.31). 
Indeed, the absorbance kept very low for non-inhibited papain, with values 
near zero (Figure 2.31, blue curve), suggesting that the protein was not 
collected during the fluorophilic elutions. However, the absorbance incresed 
for the inhibited papain, reaching the highest value after one column volume 
of methanol and inhibited papain was collected completely within two 
column volumes of methanol (Figure 2.31, orange curve). This means that 
methanol was actually able to elute the inhibited protein. 
Potentially, the excess of compound 2-4 which did not bind the protein but 
interacted with the stationary phase – because of the fluorinated alkyl chain – 
was eluted with methanol as well. To exclude any possible interference due 
to the presence of amide bonds, we analyzed a methanolic solution 
containing compound 2-4 and Coomassie Brilliant Blue by UV assay. The 
same experiment was performed with a negative control composed by only 
methanol and the dye. The absorbance values of these two samples were the 
same (0.14), proving that the presence of unbound compound 2-4 in the 
methanol washings did not interfere during UV assay.  
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Figure 2.31 Comparison of methanol elutions for non-inhibited and inhibited 
papain. 
 
Combined together, these results suggest that non-inhibited papain did not 
interact with the fluorinated stationary phase and therefore was completely 
eluted with water, as expected. Indeed, the protein was not detected in 
methanol fractions. In contrast, inhibited papain was actually able to interact 
with the fluorinated resin. In fact, papain was also collected with methanol. 
Methanol is a fluorophilic solvent able to overcome the fluorous-fluorous 
interactions between the fluorinated papain and the stationary phase, 
leading to the elution of fluorinated papain. Actually, papain was also 
collected with water. We hypothesized that the inibition of papain is a 
tedious reaction, in which the inhibitor must reach the binding pocket to 
block the enzyme. Consequently, the reaction between papain and 
compound 2-4 might not be completed. The fraction of protein collected with 
water is potentially represented by papain not bound to the fluorinated 
inhibitor and therefore not able to interact with the stationary phase. 
In conclusion, a solvent-selective elution was observed. These results let us 
hypothesize that fluorinated papain might actually be anchored to the resin, 
making this approach suitable for the fluorous proteomics strategy. 
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2.8.2 SDS-PAGE  
 
In order to prove the effectiveness of the fluorous proteomics approach, 
papain was incubated with compound 2-2 as well as with compound 2-3. 
The samples were purified by affinity chromatography and the flurophilic 
elutions were analyzed by SDS-PAGE. Figure 2.32 shows the electrophoresis 
results.  
 
 
Figure 2.32 SDS-PAGE of fluorophilic elutions of papain previously incubated with 
compound 2-2 and 2-3. 
 
 
In lane 2, an aqueous solution of the commercially available papain was 
loaded (1 mg/ml; 25 μl). Papain has a molecular weight of 23,800 Dalton and 
actually, a band at about 24 kDa was observed by SDS-PAGE. However, a 
spot at lower molecular weights (<15 kDa) was also present. Therefore, to 
investigate the quality of papain provided by Sigma Aldrich and used for 
our purposes, we analyzed papain by mass analysis. Surprisingly, we found 
that the commercially available papain was a mixture of several proteins. 
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Among them, papaya proteinase, chymopapain and caricain were present. 
These proteins belong to the papain superfamily as they are papain-like 
cysteine proteases. They are found in Carica papaya latex – as papain – and act 
as endopeptidases. These papain-like enzymes have molecular weights 
ranging from 20 to 35 kDa and share a common fold. Indeed, Cys25 and 
His159 form the catalytic site as for papain. Consequently, diazomethyl 
ketone derivatives are able to inhibit all papain-like cysteine proteases.32 
Since these proteins are endopeptidases, we hypothesized they might auto-
digested as well as be involved in the hydrolysis of papain, leading to 
peptides responsible for the spot at molecular weights lower than 15 kDa. 
The methanol elution of papain previously incubated with compound 2-3 
was loaded in lane 4. As expected, no significant band or spot was observed. 
Actually, compound 2-3 brings a fluorinated alkyl chain not long enough for 
the interaction with the stationary phase. Consequently, proteins bound to 
compound 2-3 were not retained in the column and potentially were eluted 
with water. In contrast, compound 2-2 has a longer fluorinated alkyl chain, 
able to interact with the resin during affinity chromatography. Indeed, 
protein inhibited by compound 2-2 were eluted with methanol, as 
demonstrated by SDS-PAGE (Figure 2.32, lane 6). The band referred to non-
digested inhibited papain-like enzymes (expected at about 24 kDa) was not 
observed. However, there is a clear spot at molecular weights lower than 15 
kDa, probably due to peptides derived from auto-digestion. The obtained 
results are consistent with the solvent-selective elution observed during 
affinity chromatography (Figure 2.29). 
 
2.8.3 Protein Identification 
 
The proteins eluted with methanol were investigated by mass analysis. With 
this aim, the spot observed by SDS-PAGE for the inhibited sample (Figure 
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2.32, lane 6) was excised and the proteins digested by trypsin and analyzed 
by LC-MS/MS. A bioinformatics analysis was performed matching the 
obtained mass results with Carica papaya proteome. Four proteins belonging 
to the papain superfamily were detected: papain, chymopapain, papaya 
proteinase, and caricain. The isolated proteins are cysteine endopeptidases, 
which might auto-digest as well as digest each other. Consequently, proteins 
were also present as peptides, as demonstrated by SDS-PAGE (Figure 2.32). 
Therefore, the following tryptic digestion led to the formation of shorter 
peptides. This might have complicated the mass analysis and the target 
identification as well. 
Some of the isolated peptides presented an unmodified cysteine. However, 
the peptide bearing the catalytic cysteine (Cys25) was not recovered. 
Actually, diazomethyl ketone derivatives can react only with Cys25, since the 
mechanism of this reaction involves the formation of a complex with His159, 
which is part of the catalytic triad. The fact that the peptide carrying Cys25 
bound to the fluorinated inhibitor was not observed do not compromise the 
success of the fluorous proteomics approach. Indeed, it is usual not to find all 
peptides of a digested protein in a proteomic mass analysis. Furthermore, 
papain inhibition actually occurred as previously demonstrated by UV assay 
(Figure 2.27), suggesting that the diazomethyl ketone inhibitor bound the 
protein. In addition, the ability of the fluorinated stationary phase to retain 
only the inhibited papain (Figure 2.30 and Figure 2.31) implies that the 
fluorinated inhibitor interacted with papain. The obtained results suggested 
successful interaction of compound 2-2 with the protein sample, allowing the 
anchor to the stationary phase. 
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2.9 Conclusions 
 
Chemical proteomics is a useful tool for target identification. However, it 
suffers from several disadvantages. In particular, the aspecific binding 
observed using agarose beads covalently bound to streptavidin as stationary 
phase is the main issue in traditional chemical proteomics approach. Indeed, 
proteins that interact aspecifically with the resin are often eluted with the 
biological target complicating the mass analysis. Therefore, we investigated a 
new recognition system able to afford a greater selectivity. With this aim, we 
designed an innovative fluorous proteomics technique based on the strong 
and noncovalent fluorous-fluorous interactions. In order to validate this new 
approach, papain was considered as target protein. Fluorinated diazomethyl 
ketone inhibitors were successfully synthesized and used as probes for 
applying the fluorous proteomics strategy. Only cysteine proteases 
belonging to the papain superfamily were selectively isolated by fluorophilic 
washings during affinity chromatography, demonstrating the effectiveness 
of the fluorous proteomics approach. Interestingly, papain provided by 
Sigma Aldrich was a crude Carica papaya extract (enzymatic activity ≥ 3 
U/mg), containing several proteins, papain-like cysteine proteases among 
them. The strength of the fluorous proteomics approach was demonstrated 
by the isolation of proteins showing high homology with papain and 
belonging to the papain superfamily while proteins with different structures 
were not be retained by the perfluorinated stationary phase. Therefore, the 
fluorous proteomics methodology can be successfully applied for target 
identification. 
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2.10 Experimental Section 
 
2.10.1 Materials  
 
All reagents were purchased from Sigma-Aldrich and Acros Organics. All 
solvents were of ACS grade or higher and were obtained from Sigma-Aldrich 
or Acros Organics. Columns for affinity purification were purchased from 
Fisher Scientific. All disposal materials and reagents for electrophoresis were 
purchased from Bio-Rad. Dry reactions were performed under argon using 
dry solvents and reagents. Reactions were monitored by thin-layer 
chromatography carried out on 0.25 mm Merck silica gel plates (60F-254) 
with UV light as the visualizing agent and potassium permanganate or 
phosphomolibdic acid stains as developing agents. Chromatographic 
separation was performed using Silicycle 60 Å SiO2 or Waters 2525 Binary 
Gradient Module HPLC. Purity was analyzed by HPLC VWR Hitachi Pump 
L2130. NMR spectra were recorded on Varian Mercury 300 VX (Department 
of Pharmaceutical Sciences, University of Milan) using appropriate 
deuterated solvents. Mass spectra were acquired on API 2000 LC/MS/MS 
System Package Applied Biosystem (University of Milan) and MALDI TOF-
TOF AUTOFLEX III Bruker Daltonics (Centro Interdipartimentale Grandi 
Apparecchiature, University of Milan). Protein separation was performed 
using electrophoresis cell Mini-PROTEAN® Tetra System Power PAC 300, 
Mini-PROTEAN® TGXTM Precast gel Any KDTM, Laemmli Sample Buffer 4X, 
Precision Plus Protein Standard, 10X Tris/Glycine/SDS Electrophoresis 
Buffer, Coomassie Brilliant Blue R-250. Nano LC-MS/MS analysis was 
performed using Thermo Scientific Q-Exactive mass spectrometer equipped 
with a nano-electrospray ion source (Proxeon Biosystems) and a nUPLC Easy 
97 
 
nLC 1000 (Proxeon Biosystems). (Protein Microsequencing Facility, San 
Raffaele Scientific Institute, Milan). 
  
2.10.2 Methods 
 
Purity was measured by reverse phase HPLC according to the method 
described below: 
 
Time (min) % A % B Flow (ml/min) 
0 100 0 0 
1 100 0 1 
18 0 100 1 
22 0 100 1 
24 100 0 1 
30 100 0 1 
31 100 0 0 
 
- phase A: H2O/CH3CN/TFA 97:3:0.1 
- phase B: H2O/CH3CN/TFA 30:70:0.1 
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Purification of compound 2-1 was performed using preparative HPLC, 
according to the method described below: 
 
Time (min) % A % B 
Flow 
(ml/min) 
Gradient 
0 95 5 1 linear 
1 95 5 14 linear 
20 0 100 14 linear 
25 0 100 14 linear 
26 95 5 14 linear 
30 95 5 14 linear 
31 95 5 0 linear 
 
- phase A: H2O/TFA (0.1%) 
- phase B: CH3CN/TFA (0.1%) 
 
Protein identification was performed by desalting aliquots of the sample 
containing tryptic peptides using StageTip C18. The samples were analysed 
by nLC-MS/MS using a Q-Exactive mass spectrometer equipped with a 
nano-electrospray ion source and a nUPLC Easy nLC 1000. Peptide 
separations occurred on a homemade (75 µm i.d., 12 cm long) reverse phase 
silica capillary column, packed with 1.9 µm ReproSil-Pur 120 C18-AQ (Dr. 
Maisch GmbH, Germany). A gradient of eluents A (water with 0.1% v/v 
formic acid) and B (acetonitrile with 0.1% v/v formic acid) was used to 
achieve separation (300 nL/min flow rate), from 0% B to 45% B in 45 
minutes. Full scan spectra were acquired with the lock-mass option, 
resolution set to 70,000 and mass range from m/z 300 to 2000 Da. The ten 
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most intense doubly and triply charged ions were selected and fragmented. 
All MS/MS samples were analysed using Mascot search engine (version 2.6, 
Matrix Science) to search the SwissProt Complete Proteome_2016_10 (552,884 
sequences; 197,760,918 residues), taxonomy Viridiplantae. Searches were 
performed with the following settings: trypsin as proteolytic enzyme; 3-
missed cleavages allowed; addition of 677.16 Da on cysteine, due to the 
addition of the fluorinated papain inhibitor compound 2-2, as fixed 
modification; protein N-terminus-acetylation, methionine oxidation and 
carbamidomethylation on cysteine as variable modifications; mass tolerance 
was set to 5 ppm and to 0.02 Da for precursor and fragment ions, 
respectively. 
 
2.10.3 General Synthetic Procedures 
 
Procedure 1: Coupling Reaction 
 
 
 
The carboxylic acid (1.1 eq) and the amine (1.0 eq) are dissolved in a suitable 
solvent (DMF or dichloromethane) (5 ml/mmol) under nitrogen. The 
mixture is cooled at 0 °C before adding HOBt (1.5 eq) and TBTU (1.2 eq). 
Then, NMM is added until pH=7-8. The mixture is allowed to react overnight 
at rt. The solvent is removed under reduced pressure. The residue is taken 
up in DCM and the organic phase is washed with HCl 1N, saturated aqueous 
NaHCO3, water, and brine. The organic layer is dried over Na2SO4, filtered, 
and concentrated under reduced pressure.  
 
100 
 
Procedure 2: Hydrogenolysis 
 
 
 
Benzyl-protected compound is dissolved in methanol (10 ml/mmol) and 
then 10% Pd/C (80 mg/mmol) is added. The mixture is reacted under 
hydrogen at rt and atmospheric pressure for 1 day. The mixture is filtered 
and the solvent removed under reduced pressure. The deprotected product 
is used in the following step without further purification. 
 
Procedure 3: Boc-Deprotection 
 
 
 
Boc-protected compound is cooled to 0 °C before adding HCl 4N in dioxane 
(10 ml/g of Boc-protected compound). The mixture is stirred for 30 minutes 
at rt, then the solvent is evaporated under reduced pressure and the residue 
is washed three times with ethyl ether. The deprotected product is used in 
the following step without further purification. 
 
Procedure 4: p-Tolylsulfonylmethylnitrosamine (Diazald®) Synthesis 
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A total of 100 g (0.53 mmol) of p-toluenesulfonyl chloride is divided into 
three portions of 59.4 g, 28.1 g, and 12.5 g. The first portion is added during 
about 5 minutes to 52.8 ml (0.63 mmol) of 40% aqueous methylamine 
contained in a round-bottomed flask. The mixture is allow to heat to 80-90 °C 
in order to maintain the sulfonylmethylamide in a molten condition. As soon 
as the mixture has become acidic, as indicated by testing a drop on litmus 
paper, 15.6 ml of 50% aqueous NaOH (23.5 g NaOH dissolved in 47 ml of 
H2O) is added carefully. This is followed immediately by gradual addition of 
the second portion of the p-toluenesulfonyl chloride as before. When the 
mixture has become acidic again, 7.8 ml of the aqueous NaOH solution is 
added, followed by the final portion of p-toluenesulfonyl chloride. After the 
mixture has again become acidic, the remainder of the aqueous NaOH 
solution is added. The liquid phase of the final mixture should be alkaline, 
otherwise methylamine is added to render the mixture basic. The mixture is 
stirred vigorously for 15 minutes. The hot reaction mixture is poured into 470 
ml of glacial acetic acid and the flask is rinsed clean with 80 ml of acetic acid. 
The solution is cooled in an ice bath to about 5 °C and an aqueous solution of 
NaNO2 (39.1 g dissolved in 78 ml of H2O) is added from a dropping funnel 
during about 45 minutes. The temperature of the mixture must be kept below 
10 °C, and stirring is continued for 15 minutes after addition is completed. 
During the reaction, the nitroso compound separates as a yellow crystalline 
product. 315 ml of H2O are added to the mixture. Then, the precipitate is 
separated by filtration, pressed on the funnel, and washed with about 155 ml 
of H2O. The product is transferred to a beaker, stirred well with about 125 ml 
of H2O, then filtered and washed again on the funnel. This process is 
repeated if necessary to remove the odor of acetic acid. After drying to 
constant weight under vacuo, the product melts in the range between 55 and 
60 °C.  
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Procedure 5: Diazomethane Synthesis 
 
 
 
In a round-bottom flask equipped with graduated dropping funnel and 
Claisen condenser, KOH aqueous solution (3 g dissolved in 5 ml of water), 
EtOH 95% (5 ml) and Et2O (5 ml) are added and stirred vigorously. The 
mixture is heated to 70 °C. The solvents evaporates, vapours are condensated 
and collected in a round-bottom flask kept at -20 °C. When the condensation 
starts, a solution of Diazald® (11.25 g dissolved in 65 ml of Et2O) is added 
dropwise to the evaporating mixture. Be careful during addition of Diazald® 
because explosions can occur. Diazomethane is formed and collected as 
diethyl ether solution in the round-bottom flask at -20 °C. When the reaction 
is finished, the diethyl ether solution of diazomethane (~ 50 ml) is ready to be 
used in the following step without further purification. All glassware is 
neutralized with acetic acid. 
 
Procedure 6: Diazomethyl Ketone Synthesis  
 
 
 
A solution of carboxylic acid (1 eq) and NMM (1.1 eq) in dry THF (4.7 
ml/mmol of carboxylic acid) is cooled to -15 °C before adding iBuOCOCl (1.1 
eq). Then, the reaction is stirred for 15 minutes at rt. The mixture is filtered 
and the liquid is cooled to -70 °C before adding the diethyl ether solution of 
103 
 
diazomethane. The mixture is allowed to cool at rt and react overnight. The 
solvent is evaporated under reduced pressure and the residue is taken up in 
Et2O. The organic layer is washed once with saturated aqueous NaHCO3 and 
once with brine. The organic phase is dried over Na2SO4, filtered, and 
evaporated under reduced pressure. 
 
Procedure 7: Nucleophilic Substitution of Alkoxide 
 
 
 
A solution of alcohol (0.5 eq) in dry THF (8.8 ml) is added dropwise to a 
mixture of NaH (3 eq) in dry THF (8.8 ml) under argon and the mixture is 
stirred for 1 hour at rt. Then, a solution of bromoacetic acid (1 eq) in dry THF 
(8.8 ml) is added dropwise. The mixture is stirred for 24 hours, monitoring 
the reaction by TLC. Once the reaction is completed, the excess of NaH is 
destroyed by dropwise addition of water. THF is evaporated in vacuo, and 
HCl 2M is added to the residue prior to extraction with DCM. The organic 
layer is washed with water, dried over Na2SO4, filtered and evaporated 
under reduced pressure.  
 
2.10.4 General Procedures for Fluorous Proteomics 
 
Procedure 8: Papain Activation 
 
EDTA (263 mg, 0.9 mmol) and papain (334 mg) are dissolved in 100 ml 
phosphate buffer 85 mM (pH=6.5). Then, β-mercaptoethanol (148 μl, 2.1 
mmol) is added and the solution is shaken vigorously for 1 hour. Activated 
papain is used without further purification. 
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Procedure 9: Papain Inhibition 
 
Activated papain in phosphate buffer (500 μl) is incubated with a solution of 
the inhibitor in DMF (56 mM, 45 μl). Papain inhibition is completed after 15 
minutes.  
 
Procedure 10: Affinity Chromatography Procedure 
 
The fluorinated stationary phase (1 g) is placed in a Pierce Centrifuge column 
and washed with Milli-Q water (6 CV). The protein sample is loaded and 
then incubated for 10 minutes to promote the interaction with the fluorinated 
resin. Non-fluorinated components are then gravity eluted with Milli-Q 
water (4 CV) and discarded. Then, the fluorinated components are selectively 
gravity eluted using MeOH (4 CV). The combined methanolic washings are 
dried under reduced pressure. The stationary phase can be recycled by 
washing with acetone (6 CV). 
 
Procedure 11: SDS-PAGE Purification 
 
Laemmli sample buffer 4X (12.5 μl) and DTT 200 mM (12.5 μl) are added to 
the eluted sample (25 μl) and then heated at 99 °C for 5 minutes. 
The electrophoresis cell is filled with an aqueous solution of running buffer 
(25 mM Tris, 192 mM Gly, 0.1% SDS; pH=8.3. Prepare the electrophoresis 
buffer by mixing 70 ml of the running buffer with 630 ml of fresh Milli-Q 
water).  
Polyacrylamide gel is put inside the electrophoresis tank before loading 
denaturated samples and marker into the gel wells. The tank is covered and 
the power supply is turned on to start the separation. The running voltage is 
200 V and the run time is about 30 minutes. When bromophenol blue 
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tracking dye reaches the gel bottom, the separation must be stopped. The gel 
is put in Milli-Q water and gently shaken. The Milli-Q water is then 
discarded and fresh Milli-Q water is added, keeping the gel shaken. 
 
Procedure 12: Gel Staining 
  
Coomassie Brilliant Blue is added to completely cover the gel. Then, the gel is 
gently shaken until protein bands can be observed. Coomassie staining is 
discarded and Milli-Q water is added to the gel. Milli-Q water is replenished 
several times until background of the gel is fully destained. 
 
Procedure 13: Protein Digestion 
 
Gel band is excised using a scalpel as closely to the staining boundary as 
possible. The gel band is cut and the size of gel pieces must be reduced to 1-2 
mm in each dimension to promote the peptide recovery. Gel pieces are put 
into an eppendorf and destained with 0.1 ml of destaining solution (50% 25 
mM NH4CO3/50% CH3CN). The destaining solution becomes light blue and 
can be discarded. This operation must be repeated. 0.3 ml of reducing 
solution (10 mM DTT in 50 mM NH4HCO3) are added to reduce disulfide 
bonds. The mixture is centrifuged for 45 minutes at 56 °C to 1000 rpm, then 
the reducing solution is discarded. To remove completely the reducing 
solution, gel pieces are washed with digestion buffer (50 mM NH4HCO3 in 
Milli-Q water). Then, 0.3 ml of alkylating solution (55 mM 2-iodoacetamide 
in 50 mM NH4HCO3) are added to alkylate the free thiol groups. The sample 
must be kept in the dark for 30 minutes and then is incubated with 0.9 ml 
CH3CN at rt. Gel pieces become tough and white. CH3CN is removed and 
gel pieces are allowed to dry under air. Gel pieces are treated with trypsin 
106 
 
V5111A Promega (0.21 ml) previously diluted with buffer digestion. The 
sample is shaken overnight at 37 °C. 
 
Procedure 14: Peptides Extraction 
 
TFA 50% (0.002 ml) is added to the sample to stop the protein digestion. The 
solution is collected in a new eppendorf. 0.1 ml of extraction solution (3% 
TFA/30% CH3CN in Milli-Q water) are added to the gel pieces and then are 
centrifuged at rt to 1400 rpm. The extraction solution is pipetted in the 
eppendorf containing the digested protein. Gel pieces are treated again with 
the extraction solution as described above. CH3CN (0.2 ml) is added to the 
gel pieces and are incubated for 10 minutes at rt until they become tough and 
white. CH3CN is pipetted in the same eppendorf and this operation is 
repeated. Peptides are dried under vacuum. The formation of a white or light 
blue pellet might be observed. 
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2.10.5 Specific Synthetic Procedures 
 
Intermediate 2-6 
Benzyl (tert-butoxycarbonyl)-L-phenylalanylglycinate 
 
 
Boc-L-Phe-OH and Gly benzyl ester were coupled according to general 
procedure 1 and using the following reactants: 
 
 2.59 g Boc-Phe-OH, 9.78 mmol (1.1 eq) 
  3.00 g Gly benzyl ester p-toluenesulfonate salt,  8.89 mmol (1 eq) 
 3.42 g TBTU, 10.7 mmol (1.2 eq) 
 1.80 g HOBt, 13.3 mmol (1.5 eq) 
  4.9 ml NMM, 44.4 mmol (5 eq) 
 11 ml dry DMF 
 
The reaction was monitored by TLC and then extracted with DCM.  
Intermediate 2-6 was isolated as white solid (3.28 g, 7.95 mmol, 89%). 
 
Rf = 0.81 (DCM/MeOH 9:1) 
 
1H NMR (300 MHz, Chloroform-d) δ 7.45 – 7.14 (m, 10H), 6.41 (t, J = 5.4 Hz, 
1H), 5.16 (s, 2H), 4.96 (bs, 1H), 4.40 (t, J = 7.4 Hz, 1H), 4.08 (dd, J = 18.3, 5.4 
Hz, 1H), 3.96 (dd, J = 18.4, 5.1 Hz, 1H), 3.09 (d, J = 7.5 Hz, 2H), 1.39 (s, 9H). 
 
ESI-MS, m/z: 411.22 [M-H]- 
108 
 
Intermediate 2-7 
Benzyl (tert-butoxycarbonyl)-L-leucyl-L-phenylalanylglycinate 
 
 
 
Intermediate 2-7 was obtained by coupling (general procedure 1) Boc-L-Leu-
OH and intermediate 2-6, previously deprotected according to general 
procedure 3. 
 
For the deprotection reaction, the following reagents were used: 
 32.8 ml HCl 4N in dioxan 
 3.28 g intermediate 2-6, 7.95 mmol 
 
For the coupling reaction, the following reagents were used: 
 2.18 g Boc-L-Leu-OH, 8.75 mmol (1.1 eq) 
 3.06 g TBTU, 9.54 mmol (1.2 eq) 
 1.61 g HOBt, 11.9 mmol (1.5 eq) 
 3.50 ml NMM, 31.8 mmol (4 eq) 
 23 ml dry DMF 
 
The reaction was monitored by TLC and then extracted with DCM. The 
crude product was purified by silica gel column chromatography 
(DCM/MeOH, from 100:0 to 98:2). Intermediate 2-7 was isolated as white 
solid (2.78 g, 5.29 mmol, 67%). 
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Rf = 0.88 (DCM/MeOH 9:1) 
 
1H NMR (300 MHz, Chloroform-d) δ 7.43 – 7.16 (m, 11H), 6.68 (bs, 1H), 6.48 
(d, J = 8.1 Hz, 1H), 5.15 (s, 2H), 4.79 – 4.62 (m, 2H), 4.08 (dd, J = 18.0, 6.0 Hz, 
1H), 3.91 (dd, J = 18.0, 6.0 Hz, 1H), 3.14 (d, J = 4.7 Hz, 2H), 1.68 – 1.48 (m, 3H), 
1.38 (s, 9H), 0.89 (t, J = 6.4 Hz, 6H). 
 
ESI-MS, m/z: 524.21 [M-H]- 
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Intermediate 2-8 
(2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoroheptanoyl)-L-leucyl-L-phenylalanylglycine 
 
 
 
Intermediate 2-8 was prepared by coupling (general procedure 1) 
perfluoroheptanoic acid and intermediate 2-7, previously deprotected 
according to general procedure 3. The resulting product was then 
deprotected according to general procedure 2. 
 
For the Boc-deprotection, the following reagents were used: 
 5 ml HCl 4N in dioxan 
 500 mg intermediate 2-7, 0.95 mmol 
 
For the coupling reaction, the following reagents were used: 
 484.2 mg perfluoroheptanoic acid, 1.33 mmol (1.4 eq) 
 293.0 mg DCC, 1.42 mmol (1.5 eq) 
 6.0 mg DMAP, 0.05 mmol (1/20 eq) 
 0.21 ml NMM, 1.9 mmol (2 eq) 
 5 ml DCM 
 
For the hydrogenolysis, the following reagents were used: 
 9.5 ml MeOH 
 76.0 mg 10% Pd/C 
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The coupling reaction was monitored by TLC and the mixture extracted with 
DCM. The crude product was purified by silica gel column chromatography 
(DCM/MeOH, from 100:0 to 98:2) before hydrogenolysis. Intermediate 2-8 
was isolated as white solid (115.8 mg, 0.17 mmol, 18%). 
 
Rf = 0.51 (DCM/MeOH 9:1) 
 
1H NMR (300 MHz, Methanol-d4) δ 9.26 (d, J = 8.1 Hz, 1H), 8.30 (d, J = 8.1 Hz, 
1H), 8.21 (t, J = 5.8 Hz, 1H), 7.30 – 7.13 (m, 5H), 4.72 – 4.61 (m, 1H), 4.58 – 4.47 
(m, 1H), 3.92 – 3.88 (m, 2H), 3.18 (dd, J = 13.9, 5.5 Hz, 1H), 2.94 (dd, J = 13.9, 
8.8 Hz, 1H), 1.72 – 1.48 (m, 3H), 0.93 (d, J = 5.8 Hz, 3H), 0.89 (d, J = 5.8 Hz, 
3H). 
 
19F NMR (282 MHz, Methanol-d4) δ -82.08 – -82.60 (m, 3F), -120.36 – -120.55 
(m, 2F), -120.64 – -120.88 (m, 2F), -122.52 – -122.90 (m, 2F), -123.50 – -124.11 
(m, 2F), -127.23 – -127.51 (m, 2F). 
  
ESI-MS, m/z: 680.25 [M-H]- 
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Intermediate 2-9 
Benzyl (2,2,3,3,3-pentafluoropropanoyl)-L-leucyl-L-phenylalanylglycinate 
 
 
 
Intermediate 2-7 (0.95 mmol, 1 eq) was Boc-deprotected according to general 
procedure 3, using the following reagents: 
 
 5 ml HCl 4N in dioxan 
 500 mg intermediate 2-7, 0.95 mmol 
 
Deprotected intermediate 2-7 was dissolved in DCM (3 ml) and cooled to 0 
°C. Then, TEA (0.66 ml, 4.75 mmol, 5 eq) was added to get pH=8. 
Pentafluoropropionic anhydride (0.23 ml, 1.14 mmol, 1.2 eq) was added 
dropwise and the mixture was allowed to react overnight at rt. The reaction 
was monitored by TLC. The solvent was removed under reduced pressure 
and the residue was taken up in DCM. The organic layer was washed three 
times with HCl 1N, three times with saturated aqueous NaHCO3, twice with 
water and with brine. The organic layer was dried over MgSO4, filtered and 
the solvent evaporated under reduced pressure. The crude product was 
purified by silica gel column chromatography (DCM/MeOH, from 100:0 to 
96:4). The resulting product was deprotected according to general procedure 
2 using the following reagents: 
 
 
113 
 
 8.5 ml MeOH 
 68 mg 10% Pd/C 
 
 Intermediate 2-9 was isolated as white solid (317.0 mg, 0.66 mmol, 69%). 
 
Rf = 0.15 (DCM/MeOH 9:1) 
 
1H NMR (300 MHz, Methanol-d4) δ 8.28 (d, J = 8.1 Hz, 1H), 8.20 (s, 1H), 7.40 – 
7.11 (m, 6H), 4.70 – 4.58 (m, 1H), 4.51 (dd, J = 10.6, 4.0 Hz, 1H), 3.92 – 3.84 (m, 
2H), 3.17 (dd, J = 14.1, 5.6 Hz, 1H), 2.93 (dd, J = 14.1, 8.8 Hz, 1H), 1.71 – 1.42 
(m, 3H), 0.93 (d, J = 6 Hz, 3H), 0.88 (d, J = 6 Hz, 3H). 
 
19F NMR (282 MHz, Chloroform-d) δ -81.98 – -83.14 (m, 3F), -122.15 – -123.74 
(m, 2F).  
 
ESI-MS, m/z: 480.13 [M-H]- 
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Intermediate 2-10 
2-((2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl)oxy)acetic acid 
 
 
 
Intermediate 2-10 was prepared according to general procedure 7. 
The following reagents were used: 
 
 700.0 mg 1H,1H-pentadecafluoroheptanol (1.75 mmol, 0.5 eq) in dry 
THF (8.8 ml)  
 252.0 mg NaH (10.5 mmol, 3 eq) in dry THF (8.8 ml) 
 486.3 mg bromoacetic acid (3.5 mmol, 1 eq) in dry THF (8.8 ml) 
 
Intermediate 2-10 was isolated as white solid (723.8 mg, 1.58 mmol, 90%) and 
used in the following step without further purification. 
 
Rf = 0.38 (DCM/MeOH 9:1) 
 
1H NMR (300 MHz, Chloroform-d) δ 4.33 (s, 2H), 4.13 (t, J = 13.6 Hz, 2H). 
 
19F NMR (282 MHz, Chloroform-d) δ -80.78 (t, J = 9.9 Hz, 3F), -119.68 – -
120.07 (m, 2F), -121.85 – -122.42 (m, 4F), -122.64 – -123.09 (m, 2F), -123.20 – -
123.49 (m, 2F), -125.96 – -126.34 (m, 2F).  
 
ESI-MS, m/z: 457.00 [M-H]- 
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Intermediate 2-11 
Benzyl (2-((2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl)oxy)acetyl)-L-leucyl-L-
phenylalanylglycinate 
 
 
 
Intermediate 2-11 was obtained by coupling (general procedure 1) 
intermediate 2-10 and intermediate 2-7, previously deprotected according to 
general procedure 3. 
 
For the deprotection reaction, the following reagents were used: 
 0.6 ml HCl 4N in dioxan 
 58.3 mg intermediate 2-7, 0.11 mmol 
 
For the coupling reaction, the following reagents were used: 
 71.5 mg intermediate 2-10, 0.16 mmol (1.4 eq) 
 0.027 ml DIC, 0.17 mmol (1.5 eq) 
 0.7 mg DMAP,  0.006 mmol (1/20 eq) 
 0.024 ml NMM, 0.22 mmol (2 eq) 
 2.2 ml DCM 
 
The reaction was monitored by TLC and then extracted with DCM. The 
crude product was purified by silica gel column chromatography 
(DCM/MeOH, from 100:0 to 97:3). Intermediate 2-11 was isolated as white 
solid (53.1 mg, 0.061 mmol, 55%). 
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Rf = 0.88 (DCM/MeOH 9:1) 
 
1H NMR (300 MHz, Chloroform-d) δ 7.44 – 7.14 (m, 11H), 6.60 (d, J = 7.7 Hz, 
1H), 6.52 (t, J = 5.5 Hz, 1H), 5.16 (s, 2H), 4.41 – 4.28 (m, 2H), 4.17 – 3.87 (m, 
6H), 3.16 (dd, J = 14.2, 6.5 Hz, 1H), 3.07 (dd, J = 14.2, 7.6 Hz, 1H), 1.75 – 1.38 
(m, 3H), 0.90 (d, J = 6.0 Hz, 3H), 0.87 (d, J = 6.0 Hz, 3H). 
 
19F NMR (282 MHz, Chloroform-d) δ -80.72 (t, J = 10.0 Hz, 3F), -119.45 – -
119.60 (m, 2F), -121.78 – -122.18 (m, 4F), -122.63 – -122.89 (m, 2F), -122.97 – -
123.42 (m, 2F), -125.94 – -126.19 (m, 2F). 
 
ESI-MS, m/z: 864.34 [M-H]-  
117 
 
Intermediate 2-12 
1,3-bis(2,2,3,3,3-pentafluoropropoxy)propan-2-ol 
 
 
 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluoro-1-octanol (700.0 mg, 1.75 mmol, 
3.5 eq) was heated to 120 °C before adding crushed NaOH (40.0 mg, 1 mmol, 
2 eq) under argon. The mixture was kept at 120 °C for 30 minutes. Then, 
epichlorohydrin (0.04 ml, 0.5 mmol, 1 eq) was added and the mixture was 
allowed to react overnight at this temperature. The mixture was cooled to rt, 
diluted with 180 ml distilled water and the aqueous layer was extracted with 
DCM. The organic phase was dried over Na2SO4, filtered and evaporated 
under reduced pressure. 
 
Intermediate 2-12 was isolated as oily residue (300.0 mg, 0.35 mmol, 70%) 
and used in the following step without further purification.   
 
Rf= 0.36 (cyclohexane/EtOAc 7:3) 
 
1H NMR (300 MHz, Chloroform-d) δ 4.08 – 3.86 (m, 5H), 3.70 (d, J = 4.9 Hz, 
4H), 2.28 (s, 1H). 
 
19F NMR (282 MHz, Chloroform-d) δ -80.95 (t, J = 10.1 Hz, 6F), -119.55 – -
120.09 (m, 4F), -121.94 – -122.63 (m, 8F), -122.68 – -123.22 (m, 4F), -123.32 – -
123.80 (m, 4F), -126.07 – -126.59 (m, 4F). 
 
ESI-MS, m/z: 901.10 [M+HCOO]- 
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Intermediate 2-13 
2-((1,3-bis(2,2,3,3,3-pentafluoropropoxy)propan-2-yl)oxy)acetic acid 
 
 
 
Intermediate 2-13 was prepared according to general procedure 7. 
The following reagents were used: 
 
 502.7 mg intermediate 2-12 (0.59 mmol, 0.5 eq) in dry THF (6.3 ml)  
 85.0 mg NaH (3.54 mmol, 3 eq) in dry THF (6.3 ml) 
 164.1 mg bromoacetic acid (1.18 mmol, 1 eq) in dry THF (6.3 ml) 
 
Intermediate 2-13 was isolated as yellow oil (468.8 mg, 0.51 mmol, 86%) and 
used in the following step without further purification. 
 
Rf= 0.41 (cyclohexane/EtOAc 7:3) 
 
1H NMR (300 MHz, Chloroform-d) δ 4.31 – 4.24 (m, 1H), 4.09 – 3.95 (m, 6H), 
3.71 (d, J = 4.4 Hz, 4H). 
 
19F NMR (282 MHz, Chloroform-d) δ -80.67 – -81.15 (m, 6F), -119.48 – -120.05 
(m, 4F), -121.83 – -122.54 (m, 8F), -122.59 – -123.20 (m, 4F), -123.30 – -123.80 
(m, 4F), -125.97 – -126.49 (m, 4F). 
 
ESI-MS, m/z: 456.99 [(M-2H)/2]2- 
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Intermediate 2-14 
benzyl (2-((1,3-bis((2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl)oxy)propan-2-
yl)oxy)acetyl)-L-leucyl-L-phenylalanylglycinate 
 
 
 
Intermediate 2-14 was prepared by coupling (general procedure 1) 
intermediate 2-13 and intermediate 2-7, previously deprotected according to 
general procedure 3.  
 
For the deprotection reaction, the following reagents were used: 
 1.92 ml HCl 4N in dioxan 
 191.8 mg intermediate 2-7, 0.36 mmol 
 
For the coupling reaction, the following reagents were used: 
 468.8 mg intermediate 2-13, 0.51 mmol (1.4 eq) 
 0.085 ml DIC, 0.54 mmol (1.5 eq) 
 2.44 mg DMAP,  0.02 mmol (1/20 eq) 
 0.08 ml NMM, 0.72 mmol (2 eq) 
 3.6 ml dry DMF 
 
The reaction was monitored by TLC and then extracted with DCM. The 
crude product was purified by silica gel column chromatography 
(DCM/MeOH, from 100:0 to 98:2). Intermediate 2-14 was isolated as yellow 
oil (43.8 mg, 0.033 mmol, 9%). 
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Rf= 0.96 (DCM/MeOH 9:1) 
 
1H NMR (300 MHz, Chloroform-d) δ 7.42 – 7.15 (m, 10H), 6.65 (d, J = 7.7 Hz, 
1H), 6.59 (d, J = 7.6 Hz, 1H), 6.51 (t, J = 7.0 Hz, 1H), 5.16 (s, 2H), 4.78 – 4.62 
(m, 1H), 4.42 – 4.27 (m, 1H), 4.24 – 3.83 (m, 9H), 3.82 – 3.55 (m, 4H), 3.11 (dd, J 
= 14.2, 7.1 Hz, 2H), 1.78 – 1.40 (m, 3H), 0.97 – 0.76 (m, 6H). 
 
19F NMR (282 MHz, Chloroform-d) δ -80.62 – -80.96 (m, 6F), -119.29 – -120.04 
(m, 4F), -121.87 – -122.26 (m, 8F), -122.67 – -123.01 (m, 4F), -123.06 – -123.56 
(m, 4F), -126.03 – -126.28 (m, 4F). 
 
ESI-MS, m/z: 1322.01 [M+H]+ 
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Compound 2-1 
4-nitrophenyl((benzyloxy)carbonyl)glycinate 
 
 
 
Compound 2-1 was synthesized by coupling (general procedure 1) p-
nitrophenol and Z-Gly-OH. The following reagents were used: 
 
 0.61 g Z-Gly-OH, 2.9 mmol (1.1 eq) 
 0.36 g p-nitrophenol, 2.6 mmol (1 eq) 
 1.48 g HBTU, 3.9 mmol, (1.5 eq) 
 0.35 g DMAP, 2.9 mmol (1.1 eq) 
 11 ml DCM 
 
The reaction was monitored by TLC and then extracted with DCM. The 
crude product was purified by HPLC. Compound 2-1 was isolated as white 
solid (0.54 g, 1.64 mmol, 63%). 
 
Rf = 0.72 (DCM/MeOH 9:1) 
 
1H NMR (300 MHz, Chloroform-d) δ 8.28 (d, J = 8.7 Hz, 2H), 7.42 – 7.28 (m, 
7H), 5.28 (bs, 1H), 5.17 (s, 2H), 4.28 (d, J = 5.5 Hz, 2H). 
 
ESI-MS, m/z: 329.35 [M-H]- 
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Compound 2-2 
N-((S)-1-(((S)-1-((3-diazo-2-oxopropyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-
4-methyl-1-oxopentan-2-yl)-2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoroheptanamide 
 
 
 
Compound 2-2 was synthesized following general procedure 6 from 
intermediate 2-8 and diazomethane previously prepared according to 
general procedures 4 and 5.  
 
The reagents listed below were used: 
 84.0 mg intermediate 2-8, 0.13 mmol (1 eq)  
 0.018 ml iBuOCOCl, 0.14 mmol (1.1 eq) 
 0.015 ml NMM, 0.14 mmol (1.1 eq) 
 50 ml CH2N2 
 0.6 ml dry THF 
 
Compound 2-2 was isolated as yellow oil (77.7 mg, 0.11 mmol, 85%) and 
used for fluorous proteomics without further purification. 
 
ESI-MS, m/z: 678.06 [M-N2]  
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Compound 2-3 
(S)-N-((S)-1-((3-diazo-2-oxopropyl)amino)-1-oxo-3-phenylpropan-2-yl)-4-methyl-2-
(2,2,3,3,3-pentafluoropropanamido)pentanamide 
 
 
 
Compound 2-3 was synthesized following general procedure 6 from 
intermediate 2-9 and diazomethane prepared according to general 
procedures 4 and 5. 
 
The reagents listed below were used: 
 51.0 mg intermediate 2-9, 0.11 mmol (1 eq) 
 0.016 ml iBuOCOCl, 0.12 mmol (1.1 eq) 
 0.013 ml NMM, 0.12 mmol (1.1 eq) 
 50 ml CH2N2 
 0.52 ml dry THF 
 
Compound 2-3 was isolated as yellow oil (45.7 mg, 0.09 mmol, 82%) and 
used for fluorous proteomics without further purification. 
 
ESI-MS, m/z: 478.03 [M-N2] 
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Compound 2-4 
(S)-N-((S)-1-((3-diazo-2-oxopropyl)amino)-1-oxo-3-phenylpropan-2-yl)-4-methyl-2-
(2-((2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl)oxy)acetamido)pentanamide 
 
 
 
Compound 2-4 was synthesized following general procedure 6 from 
intermediate 2-11, previously deprotected according to procedure 2, and 
diazomethane prepared according to procedures 4 and 5. 
 
For the deprotection of intermediate 2-11, the following reagents were used: 
 126.1 mg intermediate 2-11, 0.15 mmol (1 eq) 
 28.0 mg 10% Pd/C 
 3.5 ml MeOH 
 
For the synthesis of compound 2-4, the reagents listed below were used: 
 0.022 ml iBuOCOCl, 0.17 mmol (1.1 eq) 
 0.019 ml NMM, 0.17 mmol (1.1 eq) 
 50 ml CH2N2 
 0.71 ml dry THF 
 
Compound 2-4 was isolated as yellow oil (104.1 mg, 0.13 mmol, 87%) and 
used for fluorous proteomics without further purification. 
 
ESI-MS, m/z: 771.94 [M-N2] 
125 
 
Compound 2-5 
(S)-2-(2-((1,3-bis((2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl)oxy)propan-2-
yl)oxy)acetamido)-N-((S)-1-((3-diazo-2-oxopropyl)amino)-1-oxo-3-phenylpropan-2-
yl)-4-methylpentanamide 
 
 
Compound 2-5 was synthesized following general procedure 6 from 
intermediate 2-14, previously deprotected according to procedure 2, and 
diazomethane prepared according to procedures 4 and 5. 
 
For the deprotection of intermediate 2-14, the following reagents were used: 
 42.5 mg intermediate 2-14,  0.032 mmol (1 eq) 
 16 mg 10% Pd/C 
 2 ml MeOH 
 
For the synthesis of compound 2-5, the reagents listed below were used: 
 4.54 μl iBuOCOCl, 0.035 mmol (1.1 eq) 
 3.60 μl NMM,  0.035 mmol (1.1 eq) 
 50 ml CH2N2 
 0.15 ml dry THF 
 
Compound 2-5 was isolated as yellow oil (37.7 mg, 0.03 mmol, 94%) and 
used for fluorous proteomics without further purification. 
 
ESI-MS, m/z: 629.23 [(M+2H)/2]2+ 
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3.1 Fluorinated Amphiphiles for Drug Delivery 
 
Colloidal carrier systems composed of amphiphilic block copolymers 
represent an attractive route for delivery of hydrophobic drugs.1,2 Cancer 
therapy is the main field of application of these delivery systems.2,3,4 
According to estimates from the International Agency for Research on 
Cancer (IARC), by 2030 cancer is expected to grow up to 21.4 million new 
cancer cases and 13.2 million cancer deaths.5 The large majority of currently 
used anti-cancer agents are extremely toxic and a non-specific delivery is 
responsible for severe side effects. Moreover, anti-cancer drugs are highly 
hydrophobic and low soluble in aqueous, biological tissues. Due to their 
intrinsic hydrophobicity, intravenous injection of chemotherapic agents 
might lead to embolization of blood capillaries (≤ 5 μm) before reaching the 
tumor site.6 Furthermore, low solubility – coupled with metabolic 
degradation and excretion – results in poor systemic drug concentrations. 
For example, Paclitaxel (PTX) is one of the most effective chemotherapeutic 
drugs and is active against a broad range of cancers, such as lung, breast, 
ovarian, neck and head cancers as well as advanced forms of Kaposi’s 
sarcoma.7,8 However, it shows a poor water solubility (less than 0.03 
mg/ml),9 which greatly limits its widespread application in the clinical 
setting. In order to reduce the side effects of anticancer agents as well as 
increase their bioavailability, several colloidal systems have been 
investigated. Among them, polymeric micelles and nanoemulsions are the 
most promising for targeted drug delivery.  
Polymeric micelles are characterized by amphiphilic moieties that can self-
assemble into structures with hydrophobic cores and hydrophilic surfaces 
(Figure 3.1).2,10,11,12,13 Micelles are dynamic equilibrium system and are 
thermodynamically stable. The non-covalent, self-assembly occurs above the 
critical micellar concentration (CMC).6 The hydrophobic anticancer drug is 
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solubilized in the micelle core while the hydrophilic surface of the micelle 
ensures water solubility. This colloidal system has diameter in the range of 
10-100 nm.6 Because of their small sizes, polymeric micelles can reach solid 
tumor by extravasation.14,15,16  
 
 
Figure 3.1 Schematic representation of drug-loaded polymeric micelles formed from 
self-assembly of amphiphilic block copolymers in aqueous media above CMC. 
 
In contrast, nanoemulsions are heterogeneous dispersions of two immiscible 
liquids with a mean droplet diameter in the nanometric scale. 
Nanoemulsions are non-equilibrium colloidal systems. They are kinetically 
stable and energy input is required to form nanoemulsions, as shown in 
Figure 3.2. 
 
 
Figure 3.2 Schematic representation of oil-in-water emulsion formation.  
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Due to the greater size of nanoemulsions compared to micelles, a larger 
amount of drug can be loaded into nanoemulsions, making them more 
attractive for targeted drug delivery.17  
The colloidal formulations of PTX currently in clinical use are Taxol®, 
Abraxane® and Genexol-PM®. Taxol® contains Cremophor EL, a 
polyoxyethylated castor oil, as vehicle used to solubilize PTX. After 
intravenous injection of Taxol®, side effects ascribed to Cremophor EL have 
been reported.9 Indeed, severe anaphylactoid hypersensitivity reactions, 
hyperlipidaemia, abnormal lipoprotein patterns, aggregation of erythrocytes 
and peripheral neuropathy can be observed in patients treated with Taxol®.9 
Abraxane® is a nanoparticle albumin-bound PTX formulation approved by 
the FDA in 2005.18 Although Abraxane® mitigates some side effects of 
solvent-bound PTX, anemia and thrombocytopenia have still being 
reported.19 Genexol-PM® is a Cremophor EL-free polymeric micelle 
formulation of PTX with poly(ethylene glycol) (PEG) and poly(D,L-lactic 
acid).7 Although the in vivo efficacy of Genexol-PM® is 3-fold higher than 
Taxol® efficacy, its biodistribution is 2-3-fold higher in the liver, spleen, 
kidney, lung, heart and tumor cells.20,21 In the recent years, researchers have 
made efforts to develop nanocarriers with less side effects. The advantages of 
nanomedicines include their ability to protect drugs from degradation 
increasing the drug stability, improved pharmacokinetic features and 
biodistribution, tunable payload release, the ability to specifically deliver the 
drug to targeted diseased tissues and cells, and their ability to respond to 
internal and external stimuli to achieve spatial and temporal control over the 
release of therapeutic payloads.6,7,22,23,24,25 After intravenous injection, 
reticuloendothelial system (RES) – represented by monocytes and 
macrophages located in lymph nodes, spleen and liver – and renal clearance 
compete with the tumor for nanosystems.26,27 Nanosystems that escape the 
RES organs and the kidneys are able to reach the tumor. The percentage of 
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injected nanocarriers that interact with the tumor tissue is defined as the 
nanoparticle delivery efficiency.14 It has been estimated that only 0.7% of the 
injected dose (ID) of nanosystems reach the solid tumor.14 However, this 
percentage is still 10- to 100-fold higher than that of naked drug molecules.28 
Nanocarriers can get the tumor by passive or active targeting. Passive 
targeting is based on the enhanced permeability and retention (EPR) effect.26 
The tumor vasculature is abnormal and chaotic, exhibiting areas 
characterized by increased and sparse vascular density, hierarchical 
disorganization, serpentine structure and irregular branching, lack of 
innervation and smooth muscle cells, wide lumen, and includes vascular 
malformations that form arteriovenous shunts.14,29  Tumor vasculature 
develops irregularly in order to supply nutrients and oxygen needed in 
larger amount in the growing cancer. The endothelial tumor cells are poorly 
aligned, displaying large fenestrations between them. The size of these gaps 
ranges from 200 nm to 800 nm, depending on the tumor type and stage.6,30,31 
Moreover, they show disrupted basement membranes and little pericyte 
coverage.14 Blood flow behavior is unusual in cancer vessels. It has been 
observed that tumor blood flows only once in 15-20 minutes and then stops 
for a while. Moreover, blood often flows in the opposite direction.29 These 
factors combined with the increased release of vascular permeability factors – 
such as nitric oxide, bradykinin, matrix metalloproteinases (MMPs) and 
vascular endothelial growth factor (VEGF) – lead to an abnormal 
hyperpermeability, making the tumor blood vessels leaky.6,14,26 
Consequently, nanocarriers inside tumor blood vessels move slowly and this 
allows the nanosystems to diffuse out into the extracellular matrix.14 
Interestingly, major RES organs such as liver and spleen display a fenestrated 
endothelium and circulating small particles can be sequestered by EPR 
mechanism. Therefore, a large amount of systemically injected nanocarriers 
accumulates in the RES organs.27 Furthermore, the rapid cancer cell growth 
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compresses the lymph vessels, causing them to collapse, leading to a poor 
lymphatic drainage. Both the increased vascular permeability and the 
defective lymphatic drainage are responsible for the extravasation of blood 
proteins and nanosystems as well as their retention at the tumor site. Figure 
3.3 illustrates the EPR effect. 
 
 
Figure 3.3 Enhanced permeability and retention (EPR) effect and passive targeting.32 
 
Although the EPR effect plays an important role in the accumulation of 
nanocarriers in solid tumors, it shows some limitations.6 Cancer types are 
heterogeneous, being characterized by different degree of vascularization 
and vascular permeability. It is known that the central area of metastatic 
cancers is not characterized by the EPR effect and therefore the accumulation 
of macromolecules in this site is more difficult.29 Furthermore, the size of the 
gaps of the endothelial blood vessels varies within the same tumor, leading 
to areas that do not display the EPR effect. The leaky vasculature only allows 
the extravasation of nanocarriers with appropriate size and surface 
characteristics.29 Otherwise, nanocarriers might leak back into the systemic 
bloodstream and be removed from the body.  
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Since cancer cells overexpress antigens and receptors, which are absent or 
low abundant in healthy tissues, an active targeting can be used to address 
nanosystems to the tumor site allowing a selective accumulation.6,33 
Epidermal growth factor, somatostatin, transferrin, and folate receptors have 
been investigated for active targeting.6,22 Recently, peptides have been taken 
into account as targeting ligands because of their small size, lower 
immunogenicity compared to proteins, better in vivo stability, and lower 
cost.6 In particular, the arginine-glycine-aspartic acid (RGD) tripeptide has 
been widely investigated as target for integrin receptors.  
The main challenge in the development of nanosystems is their stability in 
the body. Nanocarriers should be stable for enough time in order to reach the 
cancer cells and then release the payload drug. A longer circulation lifetime 
of nanosystems is desired, since it would increase the possibility of 
nanosystems to accumulate within the tumor. Moreover, nanocarriers 
interact with blood proteins to form new biological entities called “protein 
corona” that can aggregate.14 It has been demonstrated that particles with 
cationic surfaces show the strongest macrophage uptake. Neutral polymers 
such as PEG are often conjugate to nanocarriers with the aim of masking 
these particles from macrophages and increasing their circulation lifetime. In 
fact, the coating of nanosystems with PEG leads to the formation of stealth 
particles characterized by a hydrated layer. This provides steric hindrance 
which prevents phagocytosis.29 Most importantly, the drug must remain 
confined inside the nanosystems and released only after nanocarriers have 
reached the tumor. A slower and sustained release of the drug from the 
nanocarriers might lead to a prolonged effect period against tumor cells, 
reduce the required amount of drug and decrease the systemic side effects.34   
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3.2 Background and Project Aim 
 
Amphiphilic polymers that can assembly in aqueous solution have found 
several applications in drug delivery. Among them, nanoemulsions are 
attractive drug carriers because of their kinetic stability over time as well as 
their larger oil droplet core, perfect for the shielding of hydrophobic drugs. 
However, drug release from these colloidal systems is often too fast, leading 
to burst release of drug and toxicity concerns. 
It has been demonstrated that the introduction of fluorous block to 
traditional hydrophilic-lipophilic block copolymers allows the development 
of micelles with improved kinetic and thermodynamic stability. Also, these 
semifluorinated systems are able to modulate drug time-release.35 We 
hypothesized that similar results might be achieved when semifluorinated 
polymers are used to prepare nanoemulsions. 
A new class of triblock copolymers composed by hydrophilic, fluorophilic 
and lipophilic moieties were synthesized by Professor Mecozzi group. These 
semifluorinated copolymers were used to prepare nanoemulsions for the 
delivery of hydrophobic drugs. To test the drug release profile of these 
nanoemulsions, PTX was taken into account as hydrophobic drug. In 
particular, a triphilic, linear, and semifluorinated polymer called M2F8H18 
was synthesized (Figure 3.4). 
 
 
Figure 3.4 Chemical structure of M2F8H18. 
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M2F8H18 is characterized by a linear alkyl chain of eighteen carbon atoms 
(H18) that stabilizes an oil droplet core loaded with PTX. In fact, the long 
alkyl chains penetrate the large droplet core and interact with the 
hydrophobic drug providing particle stability. The hydrophilic moiety is 
represented by a PEG unit, which ensures water solubility and is 
biocompatible. mPEG with average molecular weight of 2,000 Daltons (M2) 
was selected as hydrophilic unit to allow the most efficient packing of the 
PEG groups. Indeed, the M2 moiety shows less hydrophilic-group steric 
repulsion if compared to larger PEGs. More efficient packing directly relates 
to smaller particle sizes. It is remarkable that PEG is a common choice as 
hydrophilic component of micelles and liposomes. It is one of the few 
polymers approved by FDA as a vehicle or base in food, pharmaceuticals 
and cosmetics.36 PEG is not toxic, is eliminated intact by either the kidneys or 
the faeces and is known to lack immunogenicity. Pegylation – the process 
that binds polyethylene glycol chains to candidate molecules – has been 
exploited to prolong blood circulation time of liposomes. Indeed, pegylated 
liposomes show increased half-life, decreased plasma clearance due to the 
decreased uptake by RES organs, and a better distribution in diseased 
tissues. Moreover, it has been demonstrated that pegylated liposomes are 
less prone to leak drug before reaching the target tissue.36 
M2F8H18 bears a fluorophilic moiety placed between the hydrophilic and 
the lipophilic units. The fluorophilic portion, represented by eight CF2 
residues (F8), provides enhanced particle stability due to the formation of the 
fluorous phase. Furthermore, the fluorous shell controls the drug release 
from the core and shields the internal drug-containing oil droplet core. Due 
to the lipophobic properties of the fluorocarbon segment, it is not involved in 
the encapsulation of hydrophobic drugs.35 Oil-in-water nanoemulsions have 
been prepared using M2F8H18 and PTX. The ability of medium chain 
triglycerides (MCT) and ionic liquids (IL), such as methyltrioctylammonium 
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bis(trifluoromethylsulfonyl)imide [N1888][NTf2], to dissolve PTX was 
investigated. Both MCT and IL were excellent media to solubilize high 
concentrations of PTX (Figure 3.5). 
 
 
Figure 3.5 Chemical structures of PTX, MCT (Neobee® M-5), [N1888][NTf2] and the 
concentration of solubilized PTX in each medium. 
 
Particle size and growth of M2F8H18 nanoemulsions were monitored by 
Dynamic Light Scattering (DLS) measurements. Nanoemulsions can 
destabilize by molecular diffusion or Ostwald ripening. By this mechanism, 
individual molecules leave the smallest droplets, in which the chemical 
potential is higher due to the higher curvature, and join larger droplets. It is 
characterized by a linear increase of the droplet volume over time and by a 
time-invariant size distribution.37,38,39 Consequently, plotting particle size 
over time can give a good representation of emulsion stability. DLS study 
demonstrated that M2F8H18 nanoemulsions exhibited excellent kinetic 
stability over long periods of time (Figure 3.6). 
Media 
Concentration 
solubilized PTX 
(mg/ml) 
MCT 15 
[N1888][NTf2] 44 
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Figure 3.6 Plot of DLS measurements for nanoemulsions loaded with PTX. MCT 
and [N1888][NTf2] were taken into account as media to dissolve PTX. The stability of 
nanoemulsions containing perfluoro-15-crown-5-ether (PFCE) as 19F contrast agent 
for 19F MRI studies was also evaluated. 
 
In vitro drug release profile was also investigated. The linear M2F8H18 
nanoemulsion showed a t1/2 of 69.5 hours (Figure 3.7). Interestingly, burst 
release of PTX was not observed. The controlled drug release of the 
M2F8H18 nanoemulsion might be due both to the penetration of the long 
hydrocarbon chain of M2F8H18 into the hydrophobic core in which the 
hydrophobic drug is loaded, and to the perfluorocarbon shell surrounding 
the oil droplet. The fluorous shell forms a barrier to control drug release from 
the core as well as provides particle stability. The effect of the fluorous shell 
is demonstrated by comparing drug release half-lives from M2F8H18 
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nanoemulsions to the M2H18-based nanoemulsions lacking of the fluorous 
moiety (69.5 h and 52.9 h respectively). 
Moreover, addition of perfluroro-15-crown-5-ether (PFCE) imaging agent to 
M2F8H18 nanoemulsions increased the drug release half-life even further 
(t1/2=92.4 h) by stabilization of the hydrocarbon oil droplet (Figure 3.7). 
Therefore, PFCE shows a dual effect: it provides imaging potential to the 
nanoemulsions and enhances the modulation of drug release at the same 
time. 
 
  
Figure 3.7 Drug release profile of nanoemulsions prepared with or without PFCE. 
 
A prolonged drug release and a long half-life are desired in order to avoid 
the release of the encapsulated drug before reaching the diseased tissues. It is 
known that intravenously-injected nanoemulsions are able to get the tumor 
by EPR effect and reach peak accumulation within 12-24 hours.27 Therefore, a 
longer circulation lifetime increases the possibility for nanoemulsions to 
accumulate in the tumor and then release the drug.14 This would reduce the 
systemic toxicity and side effects. The drug release rate and the 
pharmacokinetic behavior can be modulated based on the size of the 
fluorocarbon moiety introduced in the polymer.35 In fact, the chemical 
Polymer 
Half-life 
(hrs) 
M2F8H18 69.5 
M2F8H18 92.4 
141 
 
structure and the size of the fluorinated polymer affect the formation and 
stability of the nanoemulsions and consequently the drug release rate. 
Therefore, the aim of this project was designing and synthesizing two 
triphilic, dibranched, and semifluorinated polymers to prepare 
nanoemulsions. Figure 3.8 shows the chemical structures of these dibranched 
polymers.  
 
 
Figure 3.8 Chemical structures of the triphilic, dibranched, and semifluorinated 
M2diF8H18 and M2F8H18/F8 polymers. 
 
If compared with the linear M2F8H18, the dibranched and symmetric 
M2diF8H18 is bulkier where the hydrophobic block is represented by two 
alkyl chains of eighteen carbon atoms each and two fluorous chains of eight 
CF2 residues each. In contrast, M2F8H18/F8 is an asymmetric and triphilic 
polymer in which one branch is shorter than the other one, being composed 
only by the fluorinated block. Since the alkyl chains are involved in the 
stabilization of oil droplet core while the fluorous shell gives stability to the 
colloidal system by formation of the fluorous phase, it is expected that these 
new polymers will lead to nanoemulsions with a different design that 
display differences in term of stability and drug release profile. The rationale 
is to reach a better control of the drug release by a different polymer design, 
improving the drug release half-life.  
Figure 3.9 compares the nanoemulsions design achieved with linear and 
dibranched polymers.  
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Figure 3.9 Comparison of nanoemulsions design obtained with triphilic, linear, and 
semifluorinated polymers such as M2F8H18 (left-handed) and with triphilic, 
dibranched, and semifluorinated polymers such as M2diF8H18 (right-handed). 
 
This chapter will describe the synthesis of M2diF8H18 and M2F8H18/F8. The 
preparation and purification of fluorinated molecules can be very difficult 
because of their unique chemical properties and reactivity, poor solubility in 
common organic solvents, hydrophobicity and lipophobicity, leading to 
difficulties in handling, solubilization and purification of fluorinated 
compounds.40,41 Moreover, the reactivity of fluorocarbons is greatly reduced 
when the fluorous moiety is directly bound to the reactive functional group. 
This can be explained taking into account the strong electron-withdrawing 
effect of fluoroalkyl chains.40 For these reasons, the synthesis of M2diF8H18 
and M2F8H18/F8 has been optimized in order to find the best reaction 
conditions and increase the final yield.  
Nanoemulsion design 
with triphilic, dibranched, 
and semifluorinated 
polymers 
Nanoemulsion design with 
triphilic, dibranched, and 
semifluorinated polymers 
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3.3 Polymers Synthetic Scheme 
 
The synthesis of M2diF8H18 and M2F8H18/F8 is represented in Scheme 3.1. 
 
Scheme 3.1 Synthesis of M2diF8H18 and M2F8H18/F8. 
 
Intermediate 3-6 can be achieved following either route (a) or route (b). 
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Route (a) involves the monoprotection of the commercially available 
1H,1H,10H,10H-perfluoro-1,10-decanediol (HO-F8-OH) to afford 
intermediate 3-3. Mono-benzylation reaction is chosen to protect the starting 
material HO-F8-OH and is carried out with NaH and benzyl bromide (BnBr) 
in DMF. Intermediate 3-3 is then alkylated by reaction with intermediate 3-4, 
previously prepared by mesylation of the commercially available octadecan-
1-ol. Intermediate 3-5 is achieved using benzotrifluoride (BTF) as solvent to 
promote the dissolution of intermediate 3-3. Intermediate 3-5 is then 
deprotected by hydrogenolysis over palladium on carbon to afford 
intermediate 3-6 in quantitative yield. 
The mono-benzylation of the HO-F8-OH shows a low yield (14%) and this is 
a great limitation for the whole synthesis since the monoprotection of the 
fluorous diol is the first step to get both M2diF8H18 and M2F8H18/F8 
polymers. In order to overcome this issue, a different synthetic approach is 
tested, as illustrated by route (b). In this procedure, HO-F8-OH is directly 
reacted with intermediate 3-4 to give intermediate 3-6, skipping the mono-
benzylation.41 This shortens the whole synthesis by two steps, affording the 
desired intermediate 3-6 with a good yield (33%). This reaction requires NaH 
as a base to deprotonate the HO-F8-OH and the mixture is sonicated for 21 
hours at rt. Intermediate 3-6 is then reacted with epichlorohydrin. This 
nucleophilic substitution (SN2) reaction is carried out using cyclohexane as 
solvent and an aqueous solution of NaOH as a base. Since two immiscible 
solvents (cyclohexane and water) are involved, a phase-transfer catalyst as 
tricaprylmethylammonium chloride (Aliquat 336®) is required. The mixture 
is heated to reflux for 5 hours to afford intermediate 3-7 in quantitative yield. 
Intermediate 3-7 is shared between the synthesis of M2diF8H18 and 
M2F8H18/F8. Indeed, intermediate 3-7 is coupled with intermediate 3-6 to 
afford intermediate 3-8 and is also reacted with the commercially available 
1H,1H-perfluoro-1-nonanol to give intermediate 3-9. M2diF8H18 is achieved 
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by reacting previously prepared intermediate 3-10 with intermediate 3-8 
with a low yield (10%). The synthesis of intermediate 3-10 is a mesylation 
reaction of methyl-PEG 2000 and the product is obtained in quantitative 
yield. In contrast, the pegylation of intermediate 3-8 to afford M2diF8H18 is 
quite difficult (10% yield) because of the poor reactivity of the fluorinated 
dibranched reactants as well as the steric hindrance due to the methyl-PEG 
2000. Indeed, this reaction requires a strong base as NaH, BTF as a solvent to 
solubilize the fluorinated reactants and long reaction time. Another 
important issue is the purification of crude product containing pegylated 
compounds. In fact, PEG units strongly stick on silica gel, making 
chromatography a challenge. In order to promote the purification, pegylated 
polymers might be first precipitated with ether from various solvents to 
separate the unreacted intermediate 3-10 from M2diF8H18. Then, the final 
polymer must be purified by column chromatography. In conclusion, 
M2diF8H18 was achieved while pegylation of intermediate 3-9 has not been 
attempted yet. 
 
3.4 Optimization of Selected Reactions 
 
The reactions with low yield have been optimized in order to obtain the 
desired product in a greater amount as well as reduce the consumption of the 
expensive fluorinated starting materials. In the following paragraphs, the 
optimization of the most problematic reactions is descussed. 
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3.4.1 Synthesis Optimization of Intermediate 3-3 
 
 
Scheme 3.2 Mono-benzylation of 1H,1H,10H,10H-perfluoro-1,10-decanediol 
 
Benzyl group was chosen as protecting group for 1H,1H,10H,10H-perfluoro-
1,10-decanediol since it can be removed easily by hydrogenolysis over Pd on 
carbon. 
Various reaction conditions were investigated, as shown in Table 3.1. 
 
Entry 
Reaction time 
(h) 
Temperature 
(°C) 
Dilution of 
BnBr  
Yield (%) 
1 24 rt - 2 
2 42 rt - 14 
3 46 rt 4% in DMF 10 
Table 3.1 Reaction conditions tested for the synthesis of intermediate 3-3. 
 
Previous work in Professor Mecozzi group demonstrated that the best 
reaction condition for mono-benzylation of fluorinated diols requires a 3-fold 
amount of HO-F8-OH compared to BnBr. This avoids large consumption of 
the expensive diol, giving only small amount of the di-benzylated product. 
The unreacted HO-F8-OH might be recycled and reacted again with BnBr. 
Moreover, after purification of the desired intermediate 3-3, di-benzylated 
by-product might be deprotected and purified to obtain the starting HO-F8-
OH. 
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The main issue related to this reaction is the formation of a sticky material 
after deprotonation of HO-F8-OH, making the following benzylation hard. In 
fact, as reported in Table 3.1 (entry 1) only traces of intermediate 3-3 were 
found. To investigate the influence of the reaction time, the mixture was 
allowed to react for 42 hours (Table 3.1, entry 2). In this case, intermediate 3-
3 was obtained in a low yield (14%). To better control the dripping rate of 
BnBr, this reactant was diluted in DMF and added to the mixture dropwise 
over 15 minutes (Table 3.1, entry 3). However, this did not improve the 
yield. 
With the aim of increasing the yield, a different procedure was tested for the 
mono-benzylation of HO-F8-OH.41 As shown in Scheme 3.3, the mixture was 
sonicated to promote both the deprotonation and the following benzylation. 
 
 
Scheme 3.3 Mono-benzylation of 1H,1H,10H,10H-perfluoro-1,10-decanediol.41 
 
Different conditions were investigated, as resumed in Table 3.2. 
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Entry TBAI Sonication 
Temperature 
(°C) 
Yield (%) 
1 + + rt 44 
2 - + rt 41 
3 + - rt 39 
4 - - 60 27 
Table 3.2 Reaction conditions tested for the synthesis of intermediate 3-3 applying 
the procedure proposed by Hussein et al.41 
 
All tested conditions afforded intermediate 3-3 with greater yields compared 
to those achieved with the procedure described previously. It seems that the 
presence of TBAI did not affect deeply the yield (Table 3.2, entry 1 vs entry 
2). Moreover, the yield was just a little bit higher when the reaction mixture 
was sonicated instead of stirred at rt (Table 3.2, entry 1 vs entry 3). However, 
intermediate 3-3 was obtained in a lower yield when the mixture was stirred 
and heated to 60 °C (Table 3.2, entry 4). Since heating the mixture led to a 
lower yield (Table 3.2, entry 2 vs entry 4), we hypothesized that ultrasound 
might play an important role in increasing the reaction yield while the 
temperature has not a significant impact on the yield. In fact, we supposed 
that ultrasounds break NaH particles to form a fine suspension of smaller 
NaH particles in DMF, increasing their surfaces and thus, promoting the 
deprotonation of HO-F8-OH.   
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3.4.2 Synthesis Optimization of Intermediate 3-6 
 
 
Scheme 3.4 Synthesis of intermediate 3-6. 
 
As shown in Scheme 3.1, intermediate 3-6 can be achieved starting from 
1H,1H,10H,10H-perfluoro-1,10-decanediol by mono-benzylation followed by 
alkylation of the unprotected hydroxyl group and then debenzylation (route 
a). Due to the successful benzylation of 1H,1H,10H,10H-perfluoro-1,10-
decanediol carried out with ultrasound, we hypothesized that the same 
reaction might be applied to the direct alkylation of the diol by intermediate 
3-4 (Scheme 3.1, route b). This would allow skipping the monoprotection of 
HO-F8-OH and then shortening the synthesis by two steps. 
Various reaction parameters were taken into account to optimize the direct 
alkylation of HO-F8-OH, as shown in Table 3.3.  
 
Entry 
Reaction 
solvent 
TBAI Sonication 
Temperature 
(°C) 
Reaction 
time 
(hrs) 
Yield 
(%) 
1 
DMF/THF 
7:3 
+ + rt 3 0 
2 DMF + + rt 3 28 
3 DMF + - 60 3 20 
4 DMF - - 60 21 18 
5 DMF + + rt 21 24 
6 DMF - + rt 21 33 
Table 3.3 Optimization of alkylation reaction to obtain intermediate 3-6. 
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First, a mixture of DMF and THF was used as solvent to promote the 
dissolution of all reagents (Table 3.3, entry 1). TBAI was considered as phase 
transfer catalyst and the mixture was sonicated for 3 hours. However, this 
did not lead to intermediate 3-6.  We hypothesized that THF was not a 
suitable solvent for this reaction. In fact, when the reaction was carried out 
using only DMF as solvent and keeping constant the other parameters (such 
as reaction time, temperature, the addition of TBAI as well as the sonication 
of the mixture), the formation of intermediate 3-6 was observed (28% yield; 
Table 3.3, entry 2). Then, the mixture was stirred at 60 °C both with (Table 
3.3, entry 3) and without (Table 3.3, entry 4) TBAI. In these cases, 
intermediate 3-6 was achieved with the lowest yield, according to the results 
achieved previously for the mono-benzylation of HO-F8-OH (Table 3.2). 
Then, the mixture was sonicated for 21 hours both adding TBAI (Table 3.3, 
entry 5) and without TBAI (Table 3.3, entry 6). The highest yield (33%) was 
achieved when TBAI was not added to the reaction and the mixture was 
sonicated for 21 hours (Table 3.3, entry 6). According to the previously 
obtained results for the mono-benzylation of HO-F8-OH (Table 3.2), TBAI 
seems not to be needed. According to these results, the best reaction 
conditions require the sonication of the mixture for 21 hours at room 
temperature without adding TBAI (Table 3.3, entry 6). 
The use of sound waves to generate chemical and physical effects has already 
been described in the literature. In particular, the term ”sonochemistry” is 
referred to ultrasound, that is sound waves with a frequency above 20 kHz.42  
Sonochemical reactions in solutions have mainly been explained in terms of 
cavitation theory.43 This theory assumes that the sonication leads to the 
formation, growth and implosion of microbubbles in a liquid. Ultrasound 
waves carry kinetic energy (particles of the liquid oscillate and move from 
their equilibrium position in the direction of propagation) as well as potential 
energy (fluid compression). When ultrasonic waves propagate in a liquid, the 
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local pressure in the liquid falls reaching a value lower than the vapor 
tension of that liquid. This causes the liquid to break down and microbubbles 
form. These vapor cavities are unstable and collapse rapidly. The implosion 
of the microbubbles releases a large amount of kinetic energy that drives a 
chemical reaction to completion.42,43 Both mechanical and chemical effects are 
observed in a liquid medium. Mechanical effects result in enhanced mass 
and energy transfer, particle size reduction, liquid emulsification, surface 
activation, and intense local heating. Chemical effects occur inside the 
bubbles or at the bubble interface. They are represented by molecular 
sonolysis, which includes changes in solvation. In conclusion, microbubbles – 
created by the propagation of ultrasound waves through a liquid medium – 
act as microreactors with interior environmental conditions different from 
the bulk liquid.  
The cavitation theory might explain the greater yield achieved using 
ultrasound instead of magnetic stirring for the synthesis of intermediate 3-6. 
 
The purification of intermediate 3-6 was quite simple and was achieved by 
silica gel column chromatography in gradient (hexanes and EtOAc as mobile 
phase). Despite intermediate 3-6 and unreacted intermediate 3-4 showed 
similar Rf (0.52 and 0.48 respectively), intermediate 3-6 was separated as a 
pure solid.  
 
3.4.3 Synthesis Optimization of Intermediate 3-8 
 
Scheme 3.5 General synthetic scheme for the synthesis of intermediate 3-8. 
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Scheme 3.5 shows the synthesis of intermediate 3-8 as described in the 
literature.44 A Lewis acid is needed to promote the nucleophilic oxyrane 
opening. Boron trifluoride diethyl etherate, BF3OEt2, was selected as Lewis 
acid for the tests listed in Table 3.4. 
 
Entry 
Reaction 
solvent 
Temperature 
(°C) 
Reaction 
time 
(hrs) 
Ratio 
intermediate 
3-6/ 
intermediate 
3-7/ 
BF3OEt2 
Yield 
(%) 
1 DCM rt 1 1.1 : 1 : 0.2 16 
2 DCM rt 1 1.1 : 1 : 1 18 
3 DCM rt 1 1.1 : 1 : 2 10 
4 DCM rt 1 2 : 1 : 0.2 19 
5 DCM rt 1 5 : 1 : 0.2 13 
6 DCM rt 108 2 : 1 : 1.8 13 
7 DCM rt 1 1 : 2 : 0.4 15 
8 cyclohexane rt 1 2 : 1 : 0.2 19 
9 cyclohexane reflux 1 2 : 1 : 0.2 15 
10 1,4-dioxane reflux 1 2 : 1 : 0.2 20 
11 1,4-dioxane reflux 24 2 : 1 : 0.2 22 
12 
1,2-DCE + 
BTF (1:1) 
reflux 41 2 : 1 : 0.2 14 
Table 3.4 Reaction conditions tested for the synthesis of intermediate 3-8. 
 
First, DCM was considered as solvent for this reaction and the effect of a 
different ratio among the reactants was investigated (Table 3.4, entries 1-7). 
The yields achieved varying the ratio among intermediate 3-6, intermediate 
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3-7, and the Lewis acid BF3OEt2 are very close, ranging from 10% (Table 3.4, 
entry 3) to 19% (Table 3.4, entry 4). As reported in Table 3.4, these tests were 
carried out at rt for 1 hour except for entry 6, in which the reaction time was 
significantly longer (108 hours). In this case, the aim was to verify if the low 
yield might have been due to a kinetic issue. These tests allowed us to select 
2 : 1 : 0.2 as the best ratio among intermediate 3-6, intermediate 3-7, and 
BF3OEt2 (Table 3.4, entry 4). This is consistent with the mechanism of the 
reaction, in which the Lewis acid is used as catalyst and is recycled during 
the reaction. For that reason, just a catalytic amount of BF3OEt2 is required. 
Moreover, to promote the formation of intermediate 3-8, an excess quantity 
of intermediate 3-6 was needed. However, the use of large quantities of 
intermediate 3-6 was not worth (Table 3.4, entry 5), since it did not improve 
the reaction yield. Then, the effect of the solvent, the temperature and the 
reaction time were investigated (Table 3.4, entries 8-12). Cyclohexane is the 
solvent used in the previous synthetic step, that is the synthesis of 
intermediate 3-7. Due to the good solubility of intermediate 3-6 and 
intermediate 3-7 in cyclohexane, we took into account this solvent for the 
synthesis of intermediate 3-8 (Table 3.4, entry 8 and 9). The test was 
conducted both at rt (Table 3.4, entry 8) and to reflux (81 °C) (Table 3.4, 
entry 9). The yields were consistent with those achieved previously (19% and 
15% respectively). Then, 1,4-dioxane was taken into account as solvent and 
the mixture was heated to reflux (101 °C) for 1 hour (Table 3.4, entry 10) and 
for 24 hours (Table 3.4, entry 11), without improving the yield significantly 
(20% and 22% respectively). Finally, to promote the dissolution of the 
starting materials, a mixture of two miscible solvents (1,2-DCE and BTF) was 
considered. 1,2-DCE has a chemical structure similar to DCM but the boiling 
point of 1,2-DCE is higher (83.5 °C vs 39.6 °C). This permits to reach a higher 
reaction temperature. BTF is commonly used as solvent to increase the 
solubility of fluorinated reactants by means of the fluorophilic effect. As 
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shown in Table 3.4 (entry 12) the mixture of 1,2-DCE and BTF heated to 
reflux for 41 hours did not lead to better results.  
Since the yields were low and very close to each other, we decided to 
investigate a different Lewis acid, such as TiCl4. Table 3.5 lists the reaction 
conditions tested. In all these tests, the ratio among intermediate 3-6, 
intermediate 3-7, and TiCl4 was kept as 2 : 1 : 0.2. 
 
Entry 
Reaction 
solvent 
Temperature 
(°C) 
Reaction 
time 
(hrs) 
Yield 
(%) 
1 DCM rt 1 22 
2 DCM rt 18 28 
3 1,4-dioxane reflux 24 20 
4 
1,2-DCE+BTF 
(1:1) 
reflux 1 19 
5 N(CF2CF3)3 reflux 24 21 
6 - 100 °C 1 18 
Table 3.5 Reaction conditions tested for the synthesis of intermediate 3-8 using TiCl4 
as Lewis acid. 
 
First, the reaction was carried out using DCM as solvent and stirring the 
mixture at rt for 1 hour (Table 3.5, entry 1). The yield was similar to that 
achieved when BF3OEt2 was used as Lewis acid (Table 3.5, entry 1 vs Table 
3.4, entry 4). However, when the mixture was stirred for a longer period of 
time – 18 hours instead of 1 hour – intermediate 3-8 was isolated with a 
higher yield (Table 3.5, entry 2). Then, various solvents with higher boiling 
points than DCM were tested (Table 3.5, entries 3-5). This allowed us to heat 
the mixture to reflux and investigate the effect of the temperature on the 
yield. Noteworthy, we also tested perfluorotriethylamine N(CF2CF3)3 as 
solvent (Table 3.5, entry 5), which should improve the solubility of 
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perfluorinated starting materials because of the fluorophilic effect. Moreover, 
the nitrogen atom of perfluorotriethylamine does not show basic properties 
due to the strong electron withdrawing effect of fluorines. For that reason, 
N(CF2CF3)3 can be used as solvent in reactions involving Lewis acids without 
observing a reaction between the fluorinated base and the Lewis acid.45 As 
shown in Table 3.5 (entries 3-5), heating the mixture to reflux did not 
improve the yield, not even allowing the mixture to react for 24 hours. 
Interestingly, we tried to react the mixture without using a solvent (Table 
3.5, entry 6). We reasoned that the yield might be improved increasing the 
concentration of the starting materials. To reach the highest concentration, no 
solvent was used and the solid mixture was melted. After 1 hour, 
intermediate 3-8 was isolated with low yield (18%).  
The obtained results suggested that TiCl4 worked better than BF3OEt2. 
Moreover, increasing the temperature or reacting the mixture for long time 
did not improve the yield. In conclusion, the best reaction conditions 
involved DCM as solvent and TiCl4 as catalyst. The mixture should be 
reacted at rt for 18 hours (Table 3.5, entry 2). Nevertheless, the yield 
achieved following these conditions was still low (28%).  
It is noteworthy that a mixture of intermediate 3-8 and its structural isomer 
was obtained in all tests. In fact, the nucleophilic ring-opening reaction led to 
a mixture of both secondary and primary alcohol, as shown in Figure 3.10. 
The separation of these two isomers was not possible by chromatography. 
The percentage of intermediate 3-8 in the mixture was estimated by 1H-NMR 
to be 85%, according to the literature.46 We reasoned that it is not required to 
obtain the pure intermediate 3-8 according to our purpose. Indeed, 
nanoemulsions prepared starting from a mixture of symmetric intermediate 
3-8 and its structural isomer would show the same behavior – in term of 
ability to control the drug release – than nanoemulsions composed by the 
pure intermediate 3-8. 
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Figure 3.10 Chemical structures of intermediate 3-8 (left-handed) and its structural 
isomer (right-handed) with their estimated molar percentages. 
 
Since intermediate 3-8 is a symmetric molecule, we supposed that it might be 
synthesized in one step, starting from intermediate 3-6 and epichlorohydrin, 
as shown in Scheme 3.6. 
 
 
Scheme 3.6 General synthetic scheme to obtain intermediate 3-8 in one step. 
 
This reaction requires a base like NaOH or NaH to deprotonate intermediate 
3-6 and thus promote the nucleophilic attack to the epichlorohydrin ring. 
Intermediate 3-6 was kept in excess if compared with epichlorohydrin to 
promote the formation of intermediate 3-8 instead of intermediate 3-7. Table 
3.6 summarizes the investigated reaction conditions.  
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Entry 
Reaction 
solvent 
Base 
Temperature 
(°C) 
Reaction 
time 
(hrs) 
Ratio 
intermediate 
3-6/ 
epichlorohydrin 
Yield 
(%) 
1 DMF NaH 90 18 2.1 : 1 0 
2 - KOH 100 50 3 : 1 0 
3 cyclohexane 
NaOH 
50% 
90 5 1 : 0.5 
small 
amount 
Table 3.6 Reaction conditions tested for the synthesis of intermediate 3-8 in one 
step. 
 
First, a strong base like NaH was used to deprotonate the hydroxyl group of 
intermediate 3-6.47 The mixture was heated to 90 °C for 18 hours without 
observing the formation of intermediate 3-8 (Table 3.6, entry 1). Then, a 
procedure previously used for a similar reaction by Professor Mecozzi group 
was tested (Table 3.6, entry 2). Crushed KOH and intermediate 3-6 were 
heated to 100 °C to melt the solid mass and then epichlorohydrin was added. 
The mixture was stirred for 50 hours. However, intermediate 3-8 was not 
isolated. We reasoned that intermediate 3-8 might be achieved following the 
procedure adopted for the synthesis of intermediate 3-7.44 Obviously, the 
ratio between intermediate 3-6 and epichlorohydrin must be adjusted to 
promote the isolation of intermediate 3-8 instead of intermediate 3-7 (Table 
3.6, entry 3). These conditions allowed the formation of just small amount of 
intermediate 3-8. Due to the poor achieved results, we tried a procedure 
based on ultrasounds (Table 3.7).41 This approach started with the 
deprotonation of intermediate 3-6 by crushed NaOH or NaH in the presence 
of a phase-transfer catalyst. Epichlorohydrin was added and the mixture 
stirred at rt for 24 hours and then sonicated for further 7 hours. Intermediate 
3-6 was four-fold than epichlorohydrin in terms of moles. Table 3.7 
summarizes the tested conditions. 
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Entry 
Reaction 
solvent 
Base Catalyst Yield (%) 
1 DCM 
crushed 
NaOH 
TBABr 0 
2 THF NaH TBABr 0 
3 DCM NaH TBABr 7 
4 DCM NaH TBAI 0 
Table 3.7 Reaction conditions tested for the synthesis of intermediate 3-8 in one 
step.41 
 
As shown in Table 3.7, this reaction was successful only one time (entry 3), 
where intermediate 3-8 was obtained with a very poor yield (7%). 
 
In conclusion, basic conditions were not suitable for the one step synthesis of 
intermediate 3-8. Increasing the temperature or lengthening the reaction time 
did not afford the desired product. Therefore, the symmetric intermediate 3-8 
could not be achieved in one step.  
 
3.4.4 Synthesis Optimization of Intermediate 3-9 
 
 
Scheme 3.7 General synthetic scheme for the synthesis of intermediate 3-9. 
 
Scheme 3.7 shows the synthesis of intermediate 3-9. It is similar to the 
synthesis of intermediate 3-8. Table 3.8 describes the tested conditions. 
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Entry 
Reaction 
solvent 
Lewis 
acid 
Temperature 
(°C) 
Reaction 
time 
(hrs) 
Ratio 
Perfluorononanol/ 
Intermediate 3-7/ 
Lewis acid 
Yield 
(%) 
1 DCM BF3OEt2 rt 1 1.1 : 1 : 0.2 5 
2 THF BF3OEt2 rt 1 1.1 : 1 : 0.2 0 
3 Et2O BF3OEt2 rt 1 1.1 : 1 : 0.2 0 
4 DCM BF3OEt2 rt 19 2 : 1 : 0.2 18 
5 N(CF2CF3)3 TiCl4 reflux 24 2 : 1 : 0.2 25 
6 DCM TiCl4 rt 16 3 : 1 : 0.2 30 
Table 3.8 Conditions tested for the synthesis of intermediate 3-9. 
 
As reported in Table 3.8, BF3OEt2 and TiCl4 were investigated as catalysts. 
Intermediate 3-9 was not obtained by using BF3OEt2, except when the 
reaction was carried out at rt with DCM as solvent (Table 3.8, entries 1 and 
4). Remarkably, the desired product was obtained only when a double molar 
amount of 1H,1H-perfluoro-1-nonanol compared to intermediate 3-7 was 
used, according to the results previously accomplished for the synthesis of 
intermediate 3-8 (Table 3.4). Due to the poor yields achieved with BF3OEt2, 
TiCl4 was considered as catalyst (Table 3.8, entry 5 and 6). First, N(CF2CF3)3 
was tested as solvent to promote the dissolution of fluorinated reactants. The 
mixture was heated to reflux and reacted for 24 hours, keeping the molar 
ratio among 1H,1H-perfluoro-1-nonanol, intermediate 3-7 and TiCl4 as 2 : 1 : 
0.2 (Table 3.8, entry 5). These conditions led to 25% yield. Then, DCM was 
tested as solvent (Table 3.8, entry 6). In this case, the reaction was carried out 
at rt and react for 16 hours. The molar amount of 1H,1H-perfluoro-1-nonanol 
was three-fold compared to intermediate 3-7. The yield was close to the yield 
achieved using N(CF2CF3)3 as solvent (30% vs 25% respectively). However, 
the conditions reported in Table 3.8 entry 6 were selected as the best for 
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several reasons. First, DCM is a common solvent for chemical reactions and 
less expensive than N(CF2CF3)3. Moreover, the synthetic procedure was 
simpler using DCM than N(CF2CF3)3 since the mixture was neither heated 
nor reacted for long time. The excess of 1H,1H-perfluoro-1-nonanol could be 
easily recovered during chromatography purification of the crude product 
and used again. 
 
3.5 Conclusions 
 
The triphilic, dibranched and semifluorinated polymer M2diF8H18 
(compound 3-1) has been successfully synthesized and characterized. 
However, the pegylation of intermediate 3-9 to afford M2F8H18/F8 
(compound 3-2) has not been attempted yet. The synthesis of fluorinated 
polymers is a challenge because of the poor reactivity of fluorinated starting 
materials. Moreover, their purification is difficult due to the presence of large 
PEG unit that tend to have low Rf’s and strongly stick on silica, making 
chromatography hard. Since the cost of fluorinated compounds are very high 
and the synthesis of polymers 3-1 and 3-2 requires several steps, we tried to 
increase the yield of the most problematic reactions. The most important 
improvement was the direct alkylation of the starting material 
1H,1H,10H,10H-perfluoro-1,10-decanediol to afford intermediate 3-6 
(Scheme 3.1). This allowed us to skip the mono-protection of 
1H,1H,10H,10H-perfluoro-1,10-decanediol, shorten the synthesis by two 
steps as well as increase the yield. We also tried the synthesis of the 
symmetric intermediate 3-8 in one step without good results.   
Semifluorinated polymers 3-1 and 3-2 will be used to prepare 
nanoemulsions. These colloidal systems will display an innovative design, 
different from that achieved with the linear polymer M2F2H18 (Figure 3.9). 
The new design might affect the properties of the nanoemulsions – in term of 
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stability over time and drug release profile. The evaluation of these 
properties and their comparison with those achieved for the nanoemulsions 
prepared with the linear polymer M2F2H18 will allow us to identify the best 
formulation for the controlled delivery of hydrophobic drugs.  
 
3.6 Experimental Section 
 
3.6.1 Materials and Methods 
 
All fluorinated compounds were purchased from SynQuest Laboratories, Inc. 
(Alachua, FL, USA). All other reagents were obtained from Sigma-Aldrich 
(St. Louis, MO, USA) and used as received. All solvents were of ACS grade 
or higher and were purchased from Sigma-Aldrich (St. Louis, MO, USA) or 
Fisher Scientific (Hanover Park, IL, USA). Dry reactions were performed 
under argon using dry solvents and reagents. Reactions were monitored by 
thin-layer chromatography carried out on 0.25 mm Merck silica gel plates 
(60F-254) with UV light as the visualizing agent and potassium 
permanganate stain solution as developing agent. Chromatographic 
separation was performed using Silicycle 60 Å SiO2. 1H and 19F NMR spectra 
were recorded on either Varian Unity-Inova 400 or Unity-Inova 500 
spectrometers (University of Wisconsin-Madison, WI) using appropriate 
deuterated solvents and TMS as internal reference. The final polymer was 
purified by automated flash chromatography using a CombiFlash® Rf 4x 
system (Teledyne Isco, Lincoln, NE, USA) equipped with ELSD for 
compound visualization and a REDI-Sep Rf Gold C-18 silica high 
performance aqueous reverse phase cartridge. Polymer purity was analyzed 
by HPLC with a Gilson 321 Pump (Middleton, WI) equipped with Jordi Gel 
DVB 500Å (Bellingham, MA) column and a Gilson-Prep-ELS detector. 
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MALDI spectra were acquired on a Bruker ULTRAFLEX®III and high-
resolution mass spectra were acquired on a Waters (Micromass) LCT®: 
electrospray ionization, time-of-flight, both in the University of Wisconsin-
Madison Chemistry Department.  
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3.6.2 Specific Synthetic Procedures 
 
Intermediate 3-3 
10-(benzyloxy)-2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluorodecan-1-ol 
 
 
 
METHOD A 
NaH (0.1582 g, 6.59 mmol) was added portionwise to a solution of 
1H,1H,10H,10H-perfluoro-1,10-decanediol (2.0080 g, 4.34 mmol) in 
anhydrous DMF (50 ml). The reaction mixture was stirred under argon for 1 
hour. BnBr (0.2 ml, 1.68 mmol) was diluted with DMF up to 5 ml and then 
added dropwise. The mixture was allowed to react at rt for 42 hours. The 
mixture was diluted with ether (40 ml) and extracted with aq. NH4Cl (3 X 40 
ml). The combined organic extracts were dried over MgSO4, filtered and 
evaporated in vacuo to afford a yellow oil. The residue was purified by silica 
gel column chromatography (hexanes/EtOAc 100:0 to 93:7) to yield 0.1340 g 
(0.24 mmol, 14%) white powder.  
 
Rf= 0.28 (hexanes/EtOAc 8:2) 
 
1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.30 (m, 5H), 4.68 (s, 2H), 4.10 (dt, 
J = 13.9, 7.5 Hz, 2H), 3.94 (t, J = 13.8 Hz, 2H), 1.93 (t, J = 7.6 Hz, 1H). 
 
19F NMR (376 MHz, Chloroform-d) δ -119.69 – -119.74 (m, 2F), -122.32 – -
122.45 (m, 8F), -122.77 – -122.81 (m, 2F), -123.68 – 123.71 (m, 2F), -123.95 – -
123.99 (m, 2F). 
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METHOD B 
NaH (0.1050 g, 4.37 mmol) was added portionwise to a solution of 
1H,1H,10H,10H-perfluoro-1,10-decanediol (2.0201 g, 4.37 mmol) in 
anhydrous DMF (20 ml). The reaction mixture was sonicated under argon for 
10 minutes. BnBr (0.52 ml, 4.37 mmol) and TBAI (0.6465 g, 1.75 mmol) were 
added and the mixture was sonicated for 3 hours. The solvent was 
evaporated in vacuo and the residue was taken up in 5% HCl (20 ml). This 
solution was extracted with EtOAc (3 X 20 ml). The combined organic 
extracts were washed with 0.2M Na2S2O3 (3 X 10 ml) and brine (10 ml), dried 
over MgSO4, filtered and evaporated in vacuo to afford a yellow oil. The 
residue was purified by silica gel column chromatography (hexanes/EtOAc 
100:0 to 93:7) to yield 1.0600 g (1.92 mmol, 44%) white powder, with spectra 
in agreement with those described above. 
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Intermediate 3-4 
Octadecyl methanesulfonate 
 
 
 
1-octadecanol (10.0351 g, 37.1 mmol) was dissolved in anhydrous DCM (125 
ml) and flask flushed with argon. Anhydrous TEA (12.3 ml, 89 mmol) was 
added to the solution and flask cooled in ice bath. MsCl (3.7 ml, 48.1 mmol) 
was then added dropwise and reaction stirred overnight under argon, 
allowing the mixture to warm to rt. The reaction was then stopped, diluted 
with DCM (220 ml) and washed with saturated aqueous NH4Cl (3 X 220 ml), 
dried over MgSO4 and solvent removed under vacuum to yield 12.5450 g 
(36.0 mmol, 97%) white solid. 
 
Rf= 0.48 (hexanes/EtOAc 8:2) 
 
1H NMR (400 MHz, Chloroform-d) δ 4.22 (t, J = 6.6 Hz, 2H), 3.00 (s, 3H), 1.75 
(p, J = 6.8 Hz, 2H), 1.45 – 1.10 (m, 30H), 0.88 (t, J = 6.6 Hz, 3H). 
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Intermediate 3-5 
(((2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluoro-10-(octadecyloxy)decyl)oxy) 
methyl)benzene 
 
 
 
Intermediate 3-3 (1.7912 g, 3.24 mmol) was dissolved in anhydrous BTF (50 
ml) and flask flushed with argon before NaH (0.1554 g, 6.48 mmol) was 
added. The mixture was stirred for 1 hour and then intermediate 3-4 (1.6961 
g, 4.86 mmol) was added. The mixture was heated to reflux for 24 hours. The 
reaction was allowed to cool at rt, diluted with DCM (100 ml), and washed 
with saturated aqueous NH4Cl (3 X 50 ml). The organic layer was dried over 
MgSO4 and the solvent evaporated under reduced pressure to give a pale 
yellow solid. The residue was purified by silica gel column chromatography 
(hexanes/EtOAc 88:12) to yield 1.2523 g (1.54 mmol, 46%) white solid. 
 
Rf= 0. 73 (hexanes/EtOAc 8:2) 
 
1H NMR (400 MHz, Chloroform-d): δ 7.46 – 7.29 (m, 5H), 4.68 (s, 2H), 3.97-
3.88 (m, 4H), 3.59 (t, J = 6.6 Hz, 2H), 1.60 (p, J = 7.5 Hz, 2H), 1.25 (m, 30H), 
0.88 (t, J = 6.6 Hz, 3H). 
 
19F NMR (376 MHz, Chloroform-d): δ -119.98 – -120.04 (m, 2F), -122.30 – -
122.43 (m, 8F), -122.75 – 122.85 (m, 2F), -123.76 – -123.81 (m, 2F), -123.84 – -
123.98 (m, 2F). 
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Intermediate 3-6 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluoro-10-(octadecyloxy)decan-1-ol 
 
 
 
METHOD A 
A solution of intermediate 3-5 (3.2000 g, 3.98 mmol) in methanol (250 ml) was 
flushed with argon before 10% Pd/C (400 mg) was added. Then, the mixture 
was placed under hydrogen for 2 days. The reaction was stopped and the 
mixture filtered over celite. The solvent was removed under reduced 
pressure to yield 2.7867 g (3.90 mmol, 98%) a white solid. 
 
Rf= 0.52 (hexanes/EtOAc 8:2) 
1H NMR (400 MHz, Chloroform-d) δ 4.10 (dt, J = 13.9, 16 Hz, 2H), 3.92 (t, J = 
14.0 Hz, 2H), 3.59 (t, J = 6.6 Hz, 2H), 1.93 (t, J = 7.5 Hz, 1H), 1.66 (p, J = 6.7 Hz, 
2H), 1.36 – 1.20 (m, 30H), 0.88 (t, J = 6.7 Hz, 3H). 
 
19F NMR (376 MHz, Chloroform-d) δ -119.99 – -120.06 (m, 2F), -122.29 – -
122.42 (m, 8F), -122.78 – 122.85 (m, 2F), -123.78 – -123.82 (m, 2F), -123.86 – -
123.97 (m, 2F). 
 
ESI-MS, m/z [M+NH4]+ calc’d: 732.3268; found: 732.3262. 
 
METHOD B 
NaH (1.2998 g, 54.2 mmol) was added portionwise to a solution of 
1H,1H,10H,10H-perfluoro-1,10-decanediol (24.8443 g, 53.8 mmol) in 
anhydrous DMF (500 ml). The reaction mixture was sonicated under argon 
for 10 minutes. Intermediate 3-4 (18.7594 g, 53.8 mmol) was added and the 
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mixture was sonicated for 21 hours. The solvent was evaporated in vacuo 
and the residue was taken up in 5% HCl (500 ml). This solution was 
extracted with EtOAc (3 X 500 ml). The combined organic extracts were 
washed with brine (3 X 250 ml), dried over MgSO4, filtered and evaporated 
under reduced pressure to afford a yellow oil. The residue was purified by 
silica gel column chromatography (hexanes/EtOAc 100:0 to 95:5) to yield 
12.6875 g (17.8 mmol, 33%) white powder with spectra in agreement with 
those described above.  
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Intermediate 3-7 
2-(((2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-hexadecafluoro-10-(octadecyloxy)decyl)oxy) 
methyl)oxyrane 
 
 
 
Epichlorohydrin (1.85 ml, 23.6 mmol) and Aliquat® 336 (0.14 ml, 0.31 mmol) 
were dissolved in cyclohexane (16 ml). Intermediate 3-6 (4.2222 g, 5.91 mmol) 
was added and the mixture was diluted with aqueous 50% NaOH (1.6 ml, 20 
mmol). Under vigorous stirring, the two-phase system was heated to 90 °C 
for 5 hours. The mixture was then diluted with water (200 ml) and extracted 
with DCM (3 X 600 ml). The combined organic extracts were washed with 
saturated aqueous NH4Cl (200 ml) and water (2 X 200 ml), dried over MgSO4 
and evaporated under reduced pressure to yield 4.3281 g (5.62 mmol, 95%) 
white powder.   
 
Rf=0.60 (hexanes/EtOAc 8:2) 
 
1H NMR (500 MHz, Chloroform-d) δ 4.12 – 3.89 (m, 5H), 3.59 (t, J = 6.6 Hz, 
2H), 3.54 (dd, J = 11.9 Hz, 5.9 Hz, 1H), 3.20 – 3.17 (m, 1H), 2.82 (t, J = 4.5 Hz, 
1H), 2.64 (dd, J = 4.9, 2.6 Hz, 1H), 1.65 – 1.56 (m, 2H), 1.40 – 1.17 (m, 30H), 
0.87 (t, J = 5 Hz, 3H). 
 
19F NMR (470 MHz, Chloroform-d) δ -119.52 – -119.58 (m, 2F), -119.75 – -
119.80 (m, 2F), -121.78 – -121.82 (m, 4F), -121.92 – -121.96 (m, 4F), -123.35 – -
123.38 (m, 4F). 
170 
 
Intermediate 3-8 
21,21,22,22,23,23,24,24,25,25,26,26,27,27,28,28,36,36,37,37,38,38,39,39,40,40,41, 
41,42,42,43,43-dotriacontafluoro-19,30,34,45-tetraoxatrihexacontan-32-ol 
 
 
 
Intermediate 3-6 (8.1550 g, 11.4 mmol) and intermediate 3-7 (4.4097 g, 5.72 
mmol) were dissolved in anhydrous DCM (130 ml) under argon. TiCl4 (1.14 
ml, 1.14 mmol) was added dropwise and the mixture was allowed to react 
for 18 hours at rt. The solvent was evaporated under reduced pressure and 
the residue was taken up in EtOAc (800 ml). The solution was washed with 
saturated aqueous NaHCO3 (400 ml) and brine (400 ml), dried over MgSO4, 
filtered and evaporated under reduced pressure. The residue was purified by 
silica gel column chromatography (hexanes/EtOAc 100:0 to 94:6) to yield 
2.3772 g (1.60 mmol, 28%) white powder.  
  
Rf=0.33 (hexanes/EtOAc 8:2) 
 
1H NMR (400 MHz, Chloroform-d) δ 4.07 – 4.00 (m, 5H), 3.91 (t, J = 14.0 Hz, 
4H), 3.76 (d, J = 5.0 Hz, 2H), 3.62 (dd, J = 7.5 Hz, 5.5 Hz, 2H), 3.59 (t, J = 6.0 
Hz, 4H), 2.37 (d, J = 6.0 Hz, 1H), 1.63 – 1.56 (m, 4H), 1.39 – 1.15 (m, 60 H), 0.88 
(t, J = 6.7 Hz, 6H). 
 
19F NMR (470 MHz, Chloroform-d) δ -119.54 – -119.58 (m, 8F), -121.79 – -
121.81 (m, 8F), -121.88 – -121.93 (m, 8F), -123.32 – -123.36 (m, 8F). 
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Intermediate 3-9 
21,21,22,22,23,23,24,24,25,25,26,26,27,27,28,28,36,36,37,37,38,38,39,39,40,40,41, 
41,42,42,43,43-dotriacontafluoro-19,30,34,45-tetraoxatrihexacontan-32-ol  
 
 
 
1H,1H-perfluoro-1-nonanol (8.8746 g, 19.7 mmol) and intermediate 3-7 
(5.0500 g, 6.55 mmol) were dissolved in anhydrous DCM (400 ml) under 
argon. TiCl4 (1.30 ml, 1.30 mmol) was added dropwise and the mixture was 
allowed to react for 16 hours at rt. The solvent was evaporated under 
reduced pressure and the residue was taken up in EtOAc (800 ml). The 
solution was washed with saturated aqueous NaHCO3 (400 ml) and brine 
(400 ml), dried over MgSO4, filtered and evaporated under reduced pressure. 
The residue was purified by silica gel column chromatography 
(hexanes/EtOAc 100:0 to 94:6) to yield 2.4061 g (1.97 mmol, 30%) white 
powder. 
 
Rf=0.27 (hexanes/EtOAc 8:2) 
 
1H NMR (500 MHz, Chloroform-d) δ 4.11 – 3.97 (m, 5H), 3.92 (t, J = 13.9 Hz, 
2H), 3.76 (d, J = 5.0 Hz, 2H), 3.64 (dd, J = 11.1, 5.5 Hz, 2H), 3.59 (t, J = 6.5 Hz, 
2H), 2.43 (d, J = 6.0 Hz, 1H), 1.66 – 1.54 (m, 2H), 1.40 – 1.19 (m, 30H), 0.88 (t, J 
= 6.8 Hz, 3H). 
 
19F NMR (470 MHz, Chloroform-d) δ -80.76 – -80.80 (m, 3F), -119.57 – -119.62 
(m, 6F), -121.80 – -121.85 (m, 8F), -121.88 – -121.93 (m, 8F), -123.35 – -123.37 
(m, 8F). 
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Intermediate 3-10 
mPEG2000-OMs 
 
 
 
Anhydrous TEA (2 ml, 14.4 mmol) was syringed in a solution of mPEG2000-
monomethyl ether (10.0642 g, 4.79 mmol) in anhydrous DCM (100 ml) under 
argon. MsCl (0.93 ml, 12.0 mmol) was then added and the reaction was 
stirred for 24 hours at rt under argon. The mixture was diluted with 100 ml 
DCM and washed with saturated aqueous NH4Cl (3 X 100 ml). The organic 
layer was dried over MgSO4, filtered and evaporated under reduced pressure 
to yield 10.3530 g (4.75 mmol, 99%) white solid. 
 
 1H NMR (400 MHz, Chloroform-d) δ 4.42 – 4.35 (t, J = 4 Hz 2H), 3.72 – 3.54 
(m, PEG), 3.38 (s, 3H), 3.09 (s, 3H). 
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Compound 3-1 
M2diF8H18 
 
 
 
Intermediate 3-8 (303.9 mg, 0.20 mmol) was dissolved in BTF (5 ml) and flask 
flushed with argon. The solution was cooled at 0 °C before NaH (48.5 mg, 
2.02 mmol) was added. Then, intermediate 3-10 (425.5 mg, 0.20 mmol) was 
added and the mixture heated to reflux for 5 days. The reaction was cooled, 
diluted with 150 ml DCM, washed with saturated aqueous NH4Cl (150 ml), 
brine (90 ml), and dried over MgSO4. The organics were concentrated to a 
minimum volume under reduced pressure and the product precipitated 
upon addition of cold ether. The solid was filtered and purified by silica gel 
column chromatography (DCM/methanol 100:0 to 90:10) and then by 
reverse phase column chromatography (water/methanol 100:0 to 0:100) to 
yield 68 mg (0.02 mmol, 10%) white powder. 
 
1H NMR (400 MHz, Chloroform-d) δ 4.04 – 3.97 (m, 5H), 3.95 – 3.88 (t, J = 14 
Hz, 4H), 3.83 – 3.81 (m, 2H), 3.74 – 3.55 (m, PEG), 3.48 – 3.45 (m, 2H), 3.38 (s, 
3H), 3.17 – 3.10 (t, J = 4 Hz, 4H), 1.61 – 1.56 (m, 4H), 1.35 – 1.25 (m, 60H), 0.90 
– 0.86 (t, J = 8 Hz, 6H). 
 
19F NMR (376 MHz, Chloroform-d) δ -119.66 – -119.81 (m, 8F), -121.94 – -
122.06 (m, 16F), -123.44 – -123.52 (m, 8F). 
 
Mass (MALDI): dispersion around 3458.266 
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